

List of Publications by Year in
Descending Order

Source: <https://exaly.com/author-pdf/1048141/j-y-blav-publications-by-year.pdf>
Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

973 papers	53,886 citations	116 h-index	203 g-index
1,250 ext. papers	64,043 ext. citations	5 avg, IF	7.42 L-index

#	Paper	IF	Citations
973	Wholistic approach - transcriptomic analysis and beyond using archival material for molecular diagnosis.. <i>Genes Chromosomes and Cancer</i> , 2022 ,	5	2
972	Sunitinib with concomitant radiation therapy in inoperable sarcomas: Final results from the dose escalation and expansion parts of a multicenter phase I study.. <i>Radiotherapy and Oncology</i> , 2022 ,	5.3	1
971	Survival and risk of COVID-19 after SARS-COV-2 vaccination in a series of 2391 cancer patients.. <i>European Journal of Cancer</i> , 2022 , 165, 174-183	7.5	2
970	Basket trial health technology assessment requirements and limited access to innovations in oncology: The French paradox.. <i>European Journal of Cancer</i> , 2022 , 162, 128-129	7.5	0
969	New therapeutic advances of bone sarcomas 2022 , 755-766		
968	Endoscopic management of subepithelial lesions including neuroendocrine neoplasms: European Society of Gastrointestinal Endoscopy (ESGE) Guideline.. <i>Endoscopy</i> , 2022 , 54, 412-429	3.4	8
967	The polarity and specificity of antiviral T lymphocyte responses determine susceptibility to SARS-CoV-2 infection in cancer patients and healthy individuals.. <i>Cancer Discovery</i> , 2022 ,	24.4	2
966	Improving at a nationwide level the management of patients with sarcomas with an expert network.. <i>Annals of Oncology</i> , 2022 ,	10.3	1
965	Impact of Limited E-Health Literacy on the Overall Survival of Patients With Cancer.. <i>JCO Clinical Cancer Informatics</i> , 2022 , 6, e2100174	5.2	0
964	Patterns of care and outcomes of 417 patients with METAstatic SYNovial sarcoma (METASYN): real-life data from the French Sarcoma Group (FSG).. <i>ESMO Open</i> , 2022 , 7, 100402	6	0
963	Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2101829	2.2	1
962	Phase II multicohort study of atezolizumab monotherapy in multiple advanced solid cancers.. <i>ESMO Open</i> , 2022 , 7, 100419	6	1
961	Early phase trials in soft-tissue sarcomas: clinical benefit of inclusion in early lines of treatment, molecular screening, and histology-driven trials.. <i>ESMO Open</i> , 2022 , 7, 100425	6	0
960	SELNET clinical practice guidelines for bone sarcoma.. <i>Critical Reviews in Oncology/Hematology</i> , 2022 , 174, 103685	7	0
959	Exploratory analysis of tumor imaging in a Phase 2 trial with cabozantinib in gastrointestinal stromal tumor: lessons learned from study EORTC STBSG 1317 'CaboGIST'.. <i>Acta Oncologica</i> , 2022 , 1-6	3.2	0
958	No Geographical Inequalities in Survival for Sarcoma Patients in France: A Reference Networks Outcome?. <i>Cancers</i> , 2022 , 14, 2620	6.6	0
957	Molecular profile to guide personalized medicine in adult patients with primary brain tumors: results from the ProfILER trial. <i>Medical Oncology</i> , 2021 , 39, 4	3.7	1

956	Molecular profiling of advanced soft-tissue sarcomas: the MULTISARC randomized trial. <i>BMC Cancer</i> , 2021 , 21, 1180	4.8	2
955	SELNET clinical practice guidelines for soft tissue sarcoma and GIST. <i>Cancer Treatment Reviews</i> , 2021 , 102, 102312	14.4	1
954	Precision medicine for patients with gastro-oesophageal cancer: A subset analysis of the ProFiLER program. <i>Translational Oncology</i> , 2021 , 15, 101266	4.9	2
953	Dabrafenib plus trametinib in patients with BRAF-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial. <i>Lancet Oncology</i> , 2021 ,	21.7	22
952	Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: A Sarculator-based risk stratification analysis of the ISG-STIS 1001 randomized trial. <i>Cancer</i> , 2021 , 128, 85	6.4	6
951	Radioresistance and genomic alterations in head and neck squamous cell cancer: Sub-analysis of the ProFiLER protocol. <i>Head and Neck</i> , 2021 , 43, 3899-3910	4.2	0
950	Immune infiltrates in patients with localised high-risk soft tissue sarcoma treated with neoadjuvant chemotherapy without or with regional hyperthermia: A translational research program of the EORTC 62961-ESHO 95 randomised clinical trial. <i>European Journal of Cancer</i> , 2021 , 158, 123-132	7.5	1
949	Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein of the testis carcinoma and other cancers: Results of a Phase I/II open-label, dose escalation study. <i>International Journal of Cancer</i> , 2021 ,	7.5	4
948	Denosumab Treatment for Giant Cell Tumor of the Spine Including the Sacrum. <i>Spine</i> , 2021 , 46, 277-284	3.3	7
947	Gastrointestinal stromal tumours. <i>Nature Reviews Disease Primers</i> , 2021 , 7, 22	51.1	23
946	European Reference Networks: challenges and opportunities. <i>Journal of Community Genetics</i> , 2021 , 12, 217-229	2.5	2
945	ATRX Alteration Contributes to Tumor Growth and Immune Escape in Pleomorphic Sarcomas. <i>Cancers</i> , 2021 , 13,	6.6	2
944	Inpatient comparisons of efficacy in a single-arm trial of entrectinib in tumour-agnostic indications. <i>ESMO Open</i> , 2021 , 6, 100072	6	4
943	Final analysis of the randomized trial on imatinib as an adjuvant in localized gastrointestinal stromal tumors (GIST) from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG), the Australasian Gastro-Intestinal Trials Group (AGITG), UNICANCER, French Sarcoma Group (FSG), Italian Sarcoma Group (ISG) and Spanish Sarcoma Group (SESG). <i>Annals of Oncology</i> , 2021 , 32, 100-106	10.3	5
942	Analysis of Differentiation Changes and Outcomes at Time of First Recurrence of Retroperitoneal Liposarcoma by Transatlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG). <i>Annals of Surgical Oncology</i> , 2021 , 28, 7854-7863	3.1	3
941	Ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities. <i>Cancer</i> , 2021 , 127, 2934-2942	6.4	11
940	Perioperative chemotherapy and regional hyperthermia for high-risk adult-type soft tissue sarcomas. <i>European Journal of Cancer</i> , 2021 , 147, 164-169	7.5	5
939	Determinants of the access to remote specialised services provided by national sarcoma reference centres. <i>BMC Cancer</i> , 2021 , 21, 631	4.8	3

938	ASO Visual Abstract: An Analysis of 'Differentiation' Changes and Outcomes at the 'First' Recurrence of Retroperitoneal Liposarcoma by the Transatlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG). <i>Annals of Surgical Oncology</i> , 2021 , 28, 490-491	3.1	1
937	Epithelioid hemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts. <i>ESMO Open</i> , 2021 , 6, 100170	6	11
936	Delayed care for patients with newly diagnosed cancer due to COVID-19 and estimated impact on cancer mortality in France. <i>ESMO Open</i> , 2021 , 6, 100134	6	17
935	NTRK fusion in soft tissue sarcomas harboring MDM2/CDK4 amplification: three case reports. <i>Annals of Oncology</i> , 2021 , 32, 813-814	10.3	1
934	Second primary cancers: a retrospective analysis of real world data using the enhanced medical research engine ConSoRe in a French comprehensive cancer center. <i>International Journal of Clinical Oncology</i> , 2021 , 26, 1793-1804	4.2	0
933	Mortality of patients with solid and haematological cancers presenting with symptoms of COVID-19 with vs without detectable SARS-COV-2: a French nationwide prospective cohort study. <i>British Journal of Cancer</i> , 2021 , 125, 658-671	8.7	7
932	Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors. <i>Investigational New Drugs</i> , 2021 , 39, 1587-1597	4.3	4
931	Starting Imatinib at 400 mg Daily in Patients with Gastrointestinal Stromal Tumors Harboring KIT Exon 9 Mutations: A Retrospective, Multicenter Study. <i>Targeted Oncology</i> , 2021 , 16, 485-492	5	0
930	Efficacy and safety of regorafenib in patients with metastatic or locally advanced chondrosarcoma: Results of a non-comparative, randomised, double-blind, placebo controlled, multicentre phase II study. <i>European Journal of Cancer</i> , 2021 , 150, 108-118	7.5	3
929	Severe acute respiratory syndrome coronavirus 2 vaccination for patients with solid cancer: Review and point of view of a French oncology intergroup (GCO, TNCD, UNICANCER). <i>European Journal of Cancer</i> , 2021 , 150, 232-239	7.5	7
928	Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2021 , 32, 1348-1365	10.3	48
927	A French cohort for assessing COVID-19 vaccine responses in specific populations. <i>Nature Medicine</i> , 2021 , 27, 1319-1321	50.5	6
926	Prolonged SARS-CoV-2 RNA virus shedding and lymphopenia are hallmarks of COVID-19 in cancer patients with poor prognosis. <i>Cell Death and Differentiation</i> , 2021 , 28, 3297-3315	12.7	7
925	CRYODESMO-O1: A prospective, open phase II study of cryoablation in desmoid tumour patients progressing after medical treatment. <i>European Journal of Cancer</i> , 2021 , 143, 78-87	7.5	15
924	Circulating Tumor Cells and Biomarker Modulation with Olaratumab Monotherapy Followed by Olaratumab plus Doxorubicin: Phase Ib Study in Patients with Soft-Tissue Sarcoma. <i>Molecular Cancer Therapeutics</i> , 2021 , 20, 132-141	6.1	7
923	Characterization of Macrophages and Osteoclasts in the Osteosarcoma Tumor Microenvironment at Diagnosis: New Perspective for Osteosarcoma Treatment?. <i>Cancers</i> , 2021 , 13,	6.6	5
922	Malignancy in giant cell tumor of bone: analysis of an open-label phase 2 study of denosumab. <i>BMC Cancer</i> , 2021 , 21, 89	4.8	7
921	Aldehyde Dehydrogenase, a Therapeutic Target in Chordoma: Analysis in 3D Cellular Models. <i>Cells</i> , 2021 , 10,	7.9	1

920	Continue rare cancers collaboration with European Reference Networks after Brexit. <i>Lancet, The</i> , 2021 , 397, 793	40	0
919	Management of sarcomas in children, adolescents and adults: Interactions in two different age groups under the umbrellas of GSF-GETO and SFCE, with the support of the NETSARC+ network. <i>Bulletin Du Cancer</i> , 2021 , 108, 163-176	2.4	3
918	Immune checkpoint inhibitor treatment of a first cancer is associated with a decreased incidence of second primary cancer. <i>ESMO Open</i> , 2021 , 6, 100044	6	7
917	Expression and prognostic significance of PDGF ligands and receptors across soft tissue sarcomas. <i>ESMO Open</i> , 2021 , 6, 100037	6	1
916	Nationwide incidence of sarcomas and connective tissue tumors of intermediate malignancy over four years using an expert pathology review network. <i>PLoS ONE</i> , 2021 , 16, e0246958	3.7	32
915	Metabolic landscapes in sarcomas. <i>Journal of Hematology and Oncology</i> , 2021 , 14, 114	22.4	1
914	Sarcoma management: expertise and balance. <i>Future Oncology</i> , 2021 , 17, 1	3.6	0
913	Reduced SARS-CoV-2 infection and death after two doses of COVID-19 vaccines in a series of 1503 cancer patients. <i>Annals of Oncology</i> , 2021 , 32, 1443-1444	10.3	14
912	Keeping the balance, the true major goal in advanced sarcoma. <i>Future Oncology</i> , 2021 , 17, 11-16	3.6	1
911	A randomized phase III trial comparing trabectedin to best supportive care in patients with pre-treated soft tissue sarcoma: T-SAR, a French Sarcoma Group trial. <i>Annals of Oncology</i> , 2021 , 32, 1034-1044	10.3	5
910	Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the INVICTUS Study. <i>Oncologist</i> , 2021 , 26, e2053-e2060	5.7	3
909	Checkpoint inhibition: protecting against or predisposing for second primary tumors? Reply to the Letter to the Editor 'Checkpoint inhibition: protecting against or predisposing for second primary tumors?' by K. P. M. Suijkerbuijk, A. M. May and M. J. M. van Eijs. <i>Annals of Oncology</i> , 2021 , 32, 1055-1057	10.3	
908	Predictive Value of MRP-1 in Localized High-Risk Soft Tissue Sarcomas: A Translational Research Associated to ISG-ST5 1001 Randomized Phase III Trial. <i>Molecular Cancer Therapeutics</i> , 2021 , 20, 2539-2552	6.1	0
907	Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous Mutations in the Phase III INVICTUS Study. <i>Clinical Cancer Research</i> , 2021 , 27, 6333-6342	12.9	4
906	Bamlanivimab as monotherapy in two immunocompromised patients with COVID-19. <i>Lancet Microbe, The</i> , 2021 , 2, e424	22.2	0
905	Response to letter entitled: Re: Efficacy and safety of regorafenib in patients with metastatic or locally-advanced chondrosarcoma: Results of a non-comparative, randomised, double-blind, placebo controlled, multicentre phase II study. <i>European Journal of Cancer</i> , 2021 , 157, 527-528	7.5	0
904	Bone sarcomas: ESMO-EURACAN-GENTURIS-ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2021 , 32, 1520-1536	10.3	19
903	Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2021 ,	10.3	16

902	Long-term efficacy update of crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumour from EORTC trial 90101 CREATE. <i>European Journal of Cancer</i> , 2021 , 156, 12-23	7.5	3
901	Genetic Analysis in Anal and Cervical Cancer: Exploratory Findings About Radioresistance in the ProfILER Database. <i>Cancer Genomics and Proteomics</i> , 2021 , 18, 515-520	3.3	
900	Postoperative Morbidity After Resection of Recurrent Retroperitoneal Sarcoma: A Report from the Transatlantic Australasian RPS Working Group (TARPSWG). <i>Annals of Surgical Oncology</i> , 2021 , 28, 2705-2714	21.4	6
899	Co-Targeting of MDM2 and CDK4/6 with Siremadlin and Ribociclib for the Treatment of Patients with Well-Differentiated or Dedifferentiated Liposarcoma: Results From a Proof-of-Concept, Phase Ib Study.. <i>Clinical Cancer Research</i> , 2021 ,	12.9	3
898	Medium levels of transcription and replication related chromosomal instability are associated with poor clinical outcome. <i>Scientific Reports</i> , 2021 , 11, 23429	4.9	
897	LBA68 Results of the randomized, placebo (PL)-controlled phase II study evaluating the efficacy and safety of regorafenib (REG) in patients (pts) with metastatic relapsed Ewing sarcoma (ES), on behalf of the French Sarcoma Group (FSG) and UNICANCER. <i>Annals of Oncology</i> , 2020 , 31, S1199	10.3	4
896	Pregnancy in Women with Metastatic Sarcomas. <i>Oncologist</i> , 2020 , 25, e2010-e2012	5.7	1
895	Lower detection rates of SARS-COV2 antibodies in cancer patients versus health care workers after symptomatic COVID-19. <i>Annals of Oncology</i> , 2020 , 31, 1087-1088	10.3	76
894	Neoadjuvant Chemotherapy in High-Risk Soft Tissue Sarcomas: Final Results of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups. <i>Journal of Clinical Oncology</i> , 2020 , 38, 2178-2186	2.2	57
893	Long term term follow-up of tyrosine kinase inhibitors treatments in inoperable or relapsing diffuse type tenosynovial giant cell tumors (dTGCT). <i>PLoS ONE</i> , 2020 , 15, e0233046	3.7	3
892	Dramatic response to PARP inhibition in a PALB2-mutated breast cancer: moving beyond BRCA. <i>Annals of Oncology</i> , 2020 , 31, 822-823	10.3	12
891	Activity and safety of the multi-target tyrosine kinase inhibitor cabozantinib in patients with metastatic gastrointestinal stromal tumour after treatment with imatinib and sunitinib: European Organisation for Research and Treatment of Cancer phase II trial 1317 'CaboGIST'. <i>European Journal of Cancer</i> , 2020 , 134, 62-71	7.5	21
890	Foreword. <i>Expert Review of Anticancer Therapy</i> , 2020 , 20, 1-2	3.5	1
889	MTOR signaling orchestrates stress-induced mutagenesis, facilitating adaptive evolution in cancer. <i>Science</i> , 2020 , 368, 1127-1131	33.3	33
888	Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2020 , 21, 923-934	21.7	102
887	Cabozantinib as an emerging treatment for sarcoma. <i>Current Opinion in Oncology</i> , 2020 , 32, 321-331	4.2	4
886	High mortality rate in cancer patients with symptoms of COVID-19 with or without detectable SARS-COV-2 on RT-PCR. <i>European Journal of Cancer</i> , 2020 , 135, 251-259	7.5	69
885	Imatinib in combination with phosphoinositol kinase inhibitor buparlisib in patients with gastrointestinal stromal tumour who failed prior therapy with imatinib and sunitinib: a Phase 1b, multicentre study. <i>British Journal of Cancer</i> , 2020 , 122, 1158-1165	8.7	10

884	PTPN11 mutations in canine and human disseminated histiocytic sarcoma. <i>International Journal of Cancer</i> , 2020 , 147, 1657-1665	7.5	8
883	Pharmacokinetics and safety of olaparib in patients with advanced solid tumours and mild or moderate hepatic impairment. <i>British Journal of Clinical Pharmacology</i> , 2020 , 86, 1807-1818	3.8	2
882	Quality of Surgery and Outcome in Localized Gastrointestinal Stromal Tumors Treated Within an International Intergroup Randomized Clinical Trial of Adjuvant Imatinib. <i>JAMA Surgery</i> , 2020 , 155, e200397	5.4	14
881	Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. <i>Cancer</i> , 2020 , 126, 2637-2647	6.4	31
880	Tumor Molecular Profiling: Pediatric Results of the ProFiLER Study.. <i>JCO Precision Oncology</i> , 2020 , 4, 785-795	3.6	2
879	The Activity of Chemotherapy in Inflammatory Myofibroblastic Tumors: A Multicenter, European Retrospective Case Series Analysis. <i>Oncologist</i> , 2020 , 25, e1777-e1784	5.7	10
878	Pan-Cancer Efficacy of Vemurafenib in -Mutant Non-Melanoma Cancers. <i>Cancer Discovery</i> , 2020 , 10, 657-663	6.3	46
877	Letter: Emerging Therapeutic Targets in Chordomas: A Review of the Literature in the Genomic Era. <i>Neurosurgery</i> , 2020 , 86, E480-E482	3.2	2
876	Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial. <i>Lancet Oncology, The</i> , 2020 , 21, 446-455	21.7	92
875	Assessment of Safety and Efficacy of Combined Trabectedin and Low-Dose Radiotherapy for Patients With Metastatic Soft-Tissue Sarcomas: A Nonrandomized Phase 1/2 Clinical Trial. <i>JAMA Oncology</i> , 2020 , 6, 535-541	13.4	17
874	Evolving role of regorafenib for the treatment of advanced cancers. <i>Cancer Treatment Reviews</i> , 2020 , 86, 101993	14.4	24
873	Development of a disease-specific graded prognostic assessment index for the management of sarcoma patients with brain metastases (Sarcoma-GPA). <i>BMC Cancer</i> , 2020 , 20, 117	4.8	2
872	Pazopanib for treatment of typical solitary fibrous tumours: a multicentre, single-arm, phase 2 trial. <i>Lancet Oncology, The</i> , 2020 , 21, 456-466	21.7	25
871	A double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib in non-adipocytic sarcoma patients previously treated with both chemotherapy and pazopanib. <i>European Journal of Cancer</i> , 2020 , 126, 45-55	7.5	5
870	Vemurafenib in non-small-cell lung cancer patients with BRAF and BRAF mutations. <i>Annals of Oncology</i> , 2020 , 31, 289-294	10.3	57
869	Surgical Margins and Adjuvant Therapies in Malignant Phyllodes Tumors of the Breast: A Multicenter Retrospective Study. <i>Annals of Surgical Oncology</i> , 2020 , 27, 1818-1827	3.1	8
868	The current reality of soft tissue sarcomas: advances, controversies, areas for improvement, and promising new treatments. <i>Expert Review of Anticancer Therapy</i> , 2020 , 20, 29-39	3.5	4
867	Clinical management of adolescents and young adults suffering from sarcoma in the French Rhône-Alpes region: A prospective exhaustive cohort with 10 years follow up. <i>European Journal of Surgical Oncology</i> , 2020 , 46, 1301-1309	3.6	2

866	Overview of « druggable » alterations by histological subtypes of sarcomas and connective tissue intermediate malignancies. <i>Critical Reviews in Oncology/Hematology</i> , 2020 , 150, 102960	7	1
865	First results of the EORTC-SPECTA/Arcagen study exploring the genomics of rare cancers in collaboration with the European reference network EURACAN. <i>ESMO Open</i> , 2020 , 5, e001075	6	5
864	Beyond the map: evidencing the spatial dimension of health inequalities. <i>International Journal of Health Geographics</i> , 2020 , 19, 46	3.5	10
863	Quality of life (QoL) and self-reported function with ripretinib in 4th-line therapy for patients with gastrointestinal stromal tumors (GIST): Analyses from INVICTUS.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 11535-11535	2.2	4
862	Safety profile of ripretinib, including impact of alopecia, and Palmar-Plantar Erythrodysesthesia Syndrome (PPES) on patient-reported outcomes (PROs), in 4th-line advanced gastrointestinal stromal tumors (GIST): Analyses from INVICTUS.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 11539-11539	2.2	3
861	Hyperprogression and impact of tumor growth kinetics after PD1/PDL1 inhibition in head and neck squamous cell carcinoma. <i>Oncotarget</i> , 2020 , 11, 1618-1628	3.3	6
860	The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients. <i>European Journal of Cancer</i> , 2020 , 127, 96-107	7.5	108
859	SRF-FOXO1 and SRF-NCOA1 Fusion Genes Delineate a Distinctive Subset of Well-differentiated Rhabdomyosarcoma. <i>American Journal of Surgical Pathology</i> , 2020 , 44, 607-616	6.7	22
858	SRF Fusions Other Than With RELA Expand the Molecular Definition of SRF-fused Perivascular Tumors. <i>American Journal of Surgical Pathology</i> , 2020 , 44, 1725-1735	6.7	5
857	Intrigue: Phase III study of ripretinib versus sunitinib in advanced gastrointestinal stromal tumor after imatinib. <i>Future Oncology</i> , 2020 , 16, 4251-4264	3.6	28
856	The immune landscape of chondrosarcoma reveals an immunosuppressive environment in the dedifferentiated subtypes and exposes CSFR1+ macrophages as a promising therapeutic target. <i>Journal of Bone Oncology</i> , 2020 , 20, 100271	4.5	9
855	Qualitative, Exploratory, and Multidimensional Study of Telepresence Robots for Overcoming Social Isolation of Children and Adolescents Hospitalized in Onco-Hematology. <i>Journal of Adolescent and Young Adult Oncology</i> , 2020 , 9, 90-95	2.2	4
854	A multicentric randomized phase II clinical trial evaluating high-dose thiotepa as adjuvant treatment to standard chemotherapy in patients with resectable relapsed osteosarcoma. <i>European Journal of Cancer</i> , 2020 , 125, 58-68	7.5	12
853	Impact of Metastasis Surgery and Alkylating-Agent-Based Chemotherapy on Outcomes of Metastatic Malignant Phylloides Tumors: A Multicenter Retrospective Study. <i>Annals of Surgical Oncology</i> , 2020 , 27, 1693-1699	3.1	3
852	The Oncology Data Network (ODN): A Collaborative European Data-Sharing Platform to Inform Cancer Care. <i>Oncologist</i> , 2020 , 25, e1-e4	5.7	5
851	Sarcoma European and Latin American Network (SELNET) Recommendations on Prioritization in Sarcoma Care During the COVID-19 Pandemic. <i>Oncologist</i> , 2020 , 25, e1562-e1573	5.7	3
850	Evaluation of the use and efficacy of (neo)adjuvant chemotherapy in angiosarcoma: a multicentre study. <i>ESMO Open</i> , 2020 , 5,	6	8
849	Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network. <i>Annals of Oncology</i> , 2020 , 31, 1506-1517	10.3	39

848	Risk of death of patients with cancer presenting with severe symptoms of infection, with or without documented COVID-19: In reply to van Dam et al. <i>European Journal of Cancer</i> , 2020 , 139, 68-69	7.5	
847	Progressive Desmoid Tumor: Radiomics Compared With Conventional Response Criteria for Predicting Progression During Systemic Therapy-A Multicenter Study by the French Sarcoma Group. <i>American Journal of Roentgenology</i> , 2020 , 215, 1539-1548	5.4	9
846	Therapeutic relevance of molecular screening program in patients with metastatic sarcoma: Analysis from the ProFiLER 01 trial. <i>Translational Oncology</i> , 2020 , 13, 100870	4.9	2
845	Tocilizumab for the treatment of paraneoplastic inflammatory syndrome associated with angiomatoid fibrous histiocytoma. <i>ESMO Open</i> , 2020 , 5, e000756	6	1
844	Outcomes of patients with metastatic gastrointestinal stromal tumors (GIST) treated with multi-kinase inhibitors other than imatinib as first-line treatment. <i>ESMO Open</i> , 2020 , 5, e001082	6	
843	Pharmacogenetic Study of Trabectedin-Induced Severe Hepatotoxicity in Patients with Advanced Soft Tissue Sarcoma. <i>Cancers</i> , 2020 , 12,	6.6	2
842	Long-term clinical activity, safety and patient-reported quality of life for emactuzumab-treated patients with diffuse-type tenosynovial giant-cell tumour. <i>European Journal of Cancer</i> , 2020 , 141, 162-170	7.5	4
841	Low expression of ANT1 confers oncogenic properties to rhabdomyosarcoma tumor cells by modulating metabolism and death pathways. <i>Cell Death Discovery</i> , 2020 , 6, 64	6.9	2
840	Patterns of recurrence and survival probability after second recurrence of retroperitoneal sarcoma: A study from TARPSWG. <i>Cancer</i> , 2020 , 126, 4917-4925	6.4	6
839	Reduced risk of second primary cancer in patients treated with immune checkpoint inhibitors for a first cancer. <i>Annals of Oncology</i> , 2020 , 31, 1773-1775	10.3	6
838	Specific immune landscapes and immune checkpoint expressions in histotypes and molecular subtypes of sarcoma. <i>Onc Immunology</i> , 2020 , 9, 1792036	7.2	11
837	Circulating Tumor DNA Genomics Reveal Potential Mechanisms of Resistance to BRAF-Targeted Therapies in Patients with -Mutant Metastatic Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 6242-6253	12.9	10
836	Ripretinib for advanced gastrointestinal stromal tumours - Authors' reply. <i>Lancet Oncology, The</i> , 2020 , 21, e415	21.7	3
835	Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology, The</i> , 2020 , 21, 1366-1377	21.7	84
834	Molecular Classification of Endometrial Stromal Sarcomas Using RNA Sequencing Defines Nosological and Prognostic Subgroups with Different Natural History. <i>Cancers</i> , 2020 , 12,	6.6	11
833	Real-world evidence of the efficacy and tolerability of trabectedin in patients with advanced soft-tissue sarcoma. <i>Expert Review of Anticancer Therapy</i> , 2020 , 20, 957-963	3.5	3
832	The Oncology Data Network (ODN): Methodology, Challenges, and Achievements. <i>Oncologist</i> , 2020 , 25, e1428-e1432	5.7	2
831	Assessing Prognostic and Predictive Biomarkers of Regorafenib Response in Patients with Advanced Soft Tissue Sarcoma: REGOSARC Study. <i>Cancers</i> , 2020 , 12,	6.6	2

830	Results of API-AI based regimen in osteosarcoma adult patients included in the French OS2006/Sarcome-09 study. <i>International Journal of Cancer</i> , 2020 , 146, 413-423	7.5	10
829	Systemic treatments in MDM2 positive intimal sarcoma: A multicentre experience with anthracycline, gemcitabine, and pazopanib within the World Sarcoma Network. <i>Cancer</i> , 2020 , 126, 98-104	6.4	14
828	Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma. <i>Investigational New Drugs</i> , 2020 , 38, 831-843	4.3	32
827	Local Control and Analgesic Efficacy of Percutaneous Cryoablation for Desmoid Tumors. <i>CardioVascular and Interventional Radiology</i> , 2020 , 43, 110-119	2.7	9
826	Tumor-associated macrophages and macrophage-related immune checkpoint expression in sarcomas. <i>Oncolmmunology</i> , 2020 , 9, 1747340	7.2	49
825	French Sarcoma Group proposals for management of sarcoma patients during the COVID-19 outbreak. <i>Annals of Oncology</i> , 2020 , 31, 965-966	10.3	16
824	RNA Based Approaches to Profile Oncogenic Pathways From Low Quantity Samples to Drive Precision Oncology Strategies. <i>Frontiers in Genetics</i> , 2020 , 11, 598118	4.5	8
823	Long term term follow-up of tyrosine kinase inhibitors treatments in inoperable or relapsing diffuse type tenosynovial giant cell tumors (dTGCT) 2020 , 15, e0233046		
822	Long term term follow-up of tyrosine kinase inhibitors treatments in inoperable or relapsing diffuse type tenosynovial giant cell tumors (dTGCT) 2020 , 15, e0233046		
821	Long term term follow-up of tyrosine kinase inhibitors treatments in inoperable or relapsing diffuse type tenosynovial giant cell tumors (dTGCT) 2020 , 15, e0233046		
820	Long term term follow-up of tyrosine kinase inhibitors treatments in inoperable or relapsing diffuse type tenosynovial giant cell tumors (dTGCT) 2020 , 15, e0233046		
819	Long term term follow-up of tyrosine kinase inhibitors treatments in inoperable or relapsing diffuse type tenosynovial giant cell tumors (dTGCT) 2020 , 15, e0233046		
818	Long term term follow-up of tyrosine kinase inhibitors treatments in inoperable or relapsing diffuse type tenosynovial giant cell tumors (dTGCT) 2020 , 15, e0233046		
817	Programmed cell death 1 (PD-1) targeting in patients with advanced osteosarcomas: results from the PEMBROSARC study. <i>European Journal of Cancer</i> , 2019 , 119, 151-157	7.5	51
816	Criteria for reference centers for sarcomas: volume but also long-term multidisciplinary organisation. <i>Annals of Oncology</i> , 2019 , 30, 2008-2009	10.3	6
815	Treatment of advanced soft tissue sarcoma by histological subtype: wish, prediction or reality?. <i>Future Oncology</i> , 2019 , 15, 5-10	3.6	3
814	Uveal Melanoma: A European Network to Face the Many Challenges of a Rare Cancer. <i>Cancers</i> , 2019 , 11,	6.6	4
813	Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial. <i>Lancet, The</i> , 2019 , 394, 478-487	40	148

812	Role of Chemotherapy, VEGFR Inhibitors, and mTOR Inhibitors in Advanced Perivascular Epithelioid Cell Tumors (PEComas). <i>Clinical Cancer Research</i> , 2019 , 25, 5295-5300	12.9	38
811	Adjuvant therapy with imatinib in gastrointestinal stromal tumors (GISTs)-review and perspectives. <i>Translational Gastroenterology and Hepatology</i> , 2019 , 4, 24	5.2	19
810	PARP1 expression in soft tissue sarcomas is a poor-prognosis factor and a new potential therapeutic target. <i>Molecular Oncology</i> , 2019 , 13, 1577-1588	7.9	14
809	Long lasting major response to pembrolizumab in a thoracic malignant rhabdoid-like SMARCA4-deficient tumor. <i>Annals of Oncology</i> , 2019 , 30, 1401-1403	10.3	35
808	Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages. <i>Annals of Oncology</i> , 2019 , 30, 1381-1392	10.3	74
807	Personalised management of alveolar soft part sarcoma: a promising phase 2 study. <i>Lancet Oncology, The</i> , 2019 , 20, 750-752	21.7	0
806	Successful Treatment of Metastatic Adult Wilms Tumor With Anti-BRAF Treatment: A Case Report and a Brief Review of the Literature. <i>Clinical Genitourinary Cancer</i> , 2019 , 17, e721-e723	3.3	3
805	Eribulin versus dacarbazine in patients with leiomyosarcoma: subgroup analysis from a phase 3, open-label, randomised study. <i>British Journal of Cancer</i> , 2019 , 120, 1026-1032	8.7	12
804	Survival Benefit of the Surgical Management of Retroperitoneal Sarcoma in a Reference Center: A Nationwide Study of the French Sarcoma Group from the NetSarc Database. <i>Annals of Surgical Oncology</i> , 2019 , 26, 2286-2293	3.1	36
803	International Collaborations and Regional Challenges in Providing Specialist Multidisciplinary Sarcoma Care. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019 , 39, 616-623	7.1	4
802	Can we cure patients with abdominal Desmoplastic Small Round Cell Tumor? Results of a retrospective multicentric study on 100 patients. <i>Surgical Oncology</i> , 2019 , 29, 107-112	2.5	27
801	Trabectedin and RAdiotherapy in Soft Tissue Sarcoma (TRASTS): Results of a Phase I Study in Myxoid Liposarcoma from Spanish (GEIS), Italian (ISG), French (FSG) Sarcoma Groups. <i>EClinicalMedicine</i> , 2019 , 9, 35-43	11.3	28
800	Very long-term survivors among patients with metastatic soft tissue sarcoma. <i>Cancer Medicine</i> , 2019 , 8, 1368-1378	4.8	11
799	Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProfILER trial. <i>Annals of Oncology</i> , 2019 , 30, 757-765	10.3	72
798	Surgery in reference centers improves survival of sarcoma patients: a nationwide study. <i>Annals of Oncology</i> , 2019 , 30, 1143-1153	10.3	76
797	Activity and Safety of Palbociclib in Patients with Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib: A Biomarker-driven Phase II Study. <i>Clinical Cancer Research</i> , 2019 , 25, 4611-4615	12.9	6
796	Lymphopenia in Cancer Patients and its Effects on Response to Immunotherapy: an opportunity for combination with Cytokines? 2019 , 7, 85		84
795	Localized high grade endometrial stromal sarcoma and localized undifferentiated uterine sarcoma: a retrospective series of the French Sarcoma Group. <i>International Journal of Gynecological Cancer</i> , 2019 , 29, 691-698	3.5	13

794	Sarcomas in patients over 90: Natural history and treatment-A nationwide study over 6 years. <i>International Journal of Cancer</i> , 2019 , 145, 2135-2143	7.5	6
793	Predicting Survival in Patients Undergoing Resection for Locally Recurrent Retroperitoneal Sarcoma: A Study and Novel Nomogram from TARPSWG. <i>Clinical Cancer Research</i> , 2019 , 25, 2664-2671	12.9	40
792	Impact of Concomitant Administration of Gastric Acid-Suppressive Agents and Pazopanib on Outcomes in Soft-Tissue Sarcoma Patients Treated within the EORTC 62043/62072 Trials. <i>Clinical Cancer Research</i> , 2019 , 25, 1479-1485	12.9	36
791	Networking in rare cancers: What was done, what's next. <i>European Journal of Surgical Oncology</i> , 2019 , 45, 16-18	3.6	15
790	ETIOSARC study : environmental aetiology of sarcomas from a French prospective multicentric population-based case-control study-study protocol. <i>BMJ Open</i> , 2019 , 9, e030013	3	5
789	Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses. <i>BMC Cancer</i> , 2019 , 19, 794	4.8	13
788	Efficacy of Vemurafenib in Patients With Non-Small-Cell Lung Cancer With V600 Mutation: An Open-Label, Single-Arm Cohort of the Histology-Independent VE-BASKET Study. <i>JCO Precision Oncology</i> , 2019 , 3,	3.6	15
787	Gastrointestinal stromal tumours (GISTs): French Intergroup Clinical Practice Guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO). <i>Digestive and Liver Disease</i> , 2019 , 51, 1223-1231	3.3	28
786	Pazopanib or methotrexate-vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study. <i>Lancet Oncology</i> , 2019 , 20, 1263-1272	21.7	69
785	Pazopanib for treatment of advanced extraskeletal myxoid chondrosarcoma: a multicentre, single-arm, phase 2 trial. <i>Lancet Oncology</i> , 2019 , 20, 1252-1262	21.7	34
784	Challenges in the value assessment, pricing and funding of targeted combination therapies in oncology. <i>Health Policy</i> , 2019 , 123, 1230-1236	3.2	5
783	Actionable molecular alterations in advanced gynaecologic malignancies: updated results from the ProfILER programme. <i>European Journal of Cancer</i> , 2019 , 118, 156-165	7.5	5
782	Watch and Wait Approach for Re-excision After Unplanned Yet Macroscopically Complete Excision of Extremity and Superficial Truncal Soft Tissue Sarcoma is Safe and Does Not Affect Metastatic Risk or Amputation Rate. <i>Annals of Surgical Oncology</i> , 2019 , 26, 3526-3534	3.1	23
781	Expression of lymphocyte immunoregulatory biomarkers in bone and soft-tissue sarcomas. <i>Modern Pathology</i> , 2019 , 32, 1772-1785	9.8	33
780	Recurrent DMD Deletions Highlight Specific Role of Dp71 Isoform in Soft-Tissue Sarcomas. <i>Cancers</i> , 2019 , 11,	6.6	10
779	A first in human, phase I trial of NP137, a first-in-class antibody targeting netrin-1, in patients with advanced refractory solid tumors. <i>Annals of Oncology</i> , 2019 , 30, v159	10.3	6
778	CRYODESMO-O1: A French nationwide phase II study on cryoablation in progressing desmoid tumour (DT) patients (pts). <i>Annals of Oncology</i> , 2019 , 30, v683	10.3	3
777	INVICTUS: A phase III, interventional, double-blind, placebo-controlled study to assess the safety and efficacy of ripretinib as 4th-line therapy in patients with advanced gastrointestinal stromal tumors (GIST) who have received treatment with prior anticancer therapies (NCT03353753). <i>Annals of Oncology</i> , 2019 , 30, v825-v826	10.3	7

776	Long-term efficacy of imatinib mesylate in patients with advanced Tenosynovial Giant Cell Tumor. <i>Scientific Reports</i> , 2019 , 9, 14551	4.9	16
775	Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study. <i>Lancet Oncology, The</i> , 2019 , 20, 1719-1729	21.7	74
774	Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: Final results of a randomized clinical trial from the Italian Sarcoma Group, the Spanish Sarcoma Group (GEIS), the French Sarcoma Group (FSG), and the Polish Sarcoma Group (PSG).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 11000-11000	2.2	2
773	Pamiparib, an investigational PARP inhibitor, in patients with metastatic castration-resistant prostate cancer (mCRPC) and a circulating tumor cell (CTC) homologous recombination deficiency (HRD) phenotype or BRCA defects: A trial in progress.. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS5086-TPS5086	2.2	5
772	A phase II trial in progress: Pamiparib, an investigational PARP inhibitor, in patients with metastatic castration-resistant prostate cancer and a circulating tumor cell homologous recombination deficiency (HRD) phenotype or BRCA defects.. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS328-TPS328	2.2	
771	Proof-of-concept study evaluating a new tool for standardizing radiological assessment of tumor response to treatment in routine clinical practice.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e18079-e18079 ^{2.2}		
770	Personalised Follow-up Program after Acute Phase of Treatment in Oncology/Hematology Patients Towards Early Intervention, Better Care and Quality of Life Improvement: Results from Pasca Pilot Study. <i>Blood</i> , 2019 , 134, 5817-5817	2.2	0
769	Outcome of Patients with Soft-Tissue Sarcomas: An Age-Specific Conditional Survival Analysis. <i>Oncologist</i> , 2019 , 24, e559-e564	5.7	3
768	Brain Metastases and Place of Antiangiogenic Therapies in Alveolar Soft Part Sarcoma: A Retrospective Analysis of the French Sarcoma Group. <i>Oncologist</i> , 2019 , 24, 980-988	5.7	6
767	Redefining malignant pleural mesothelioma types as a continuum uncovers immune-vascular interactions. <i>EBioMedicine</i> , 2019 , 48, 191-202	8.8	31
766	Deep learning-based classification of mesothelioma improves prediction of patient outcome. <i>Nature Medicine</i> , 2019 , 25, 1519-1525	50.5	132
765	SMARCA4-deficient Thoracic Sarcomas: Clinicopathologic Study of 30 Cases With an Emphasis on Their Nosology and Differential Diagnoses. <i>American Journal of Surgical Pathology</i> , 2019 , 43, 455-465	6.7	64
764	Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial. <i>Lancet Oncology, The</i> , 2019 , 20, 134-144	21.7	58
763	Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study. <i>Lancet Oncology, The</i> , 2019 , 20, 120-133	21.7	134
762	Patterns of Care and Outcome Radiation-Induced Soft Tissue Sarcomas. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019 , 103, 449-452	4	3
761	RCBTB1 Deletion Is Associated with Metastatic Outcome and Contributes to Docetaxel Resistance in Nontranslocation-Related Pleomorphic Sarcomas. <i>Cancers</i> , 2019 , 11,	6.6	3
760	Impact of Trabectedin Interruption and Subsequent Rechallenge on Progression in Patients With Advanced Soft Tissue Sarcoma: Long-term Follow-up of the T-DIS trial. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018 , 41, 1094-1100	2.7	7
759	A comparison of Australian and French families affected by sarcoma: perceptions of genetics and incidental findings. <i>Personalized Medicine</i> , 2018 , 15, 13-24	2.2	

758	Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial. <i>Lancet Respiratory Medicine</i> , 2018 , 6, 431-441	35.1	87
757	Using biology to guide the treatment of sarcomas and aggressive connective-tissue tumours. <i>Nature Reviews Clinical Oncology</i> , 2018 , 15, 443-458	19.4	27
756	Complete response to CSF1R inhibitor in a translocation variant of teno-synovial giant cell tumor without genomic alteration of the CSF1 gene. <i>Annals of Oncology</i> , 2018 , 29, 1488-1489	10.3	6
755	Anthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma: A Multi-institutional Case Series. <i>JAMA Oncology</i> , 2018 , 4, e180219	13.4	46
754	Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first-line chemotherapy: An exploratory, retrospective analysis of the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG). <i>International Journal of Cancer</i> , 2018 , 142, 2610-2620	7.5	22
753	Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 'CREATE'. <i>Annals of Oncology</i> , 2018 , 29, 758-765	10.3	44
752	European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Experience with Advanced/Metastatic Epithelioid Sarcoma Patients Treated in Prospective Trials: Clinical Profile and Response to Systemic Therapy. <i>Clinical Oncology</i> , 2018 , 30, 448-454	2.8	17
751	Nilotinib in locally advanced pigmented villonodular synovitis: a multicentre, open-label, single-arm, phase 2 trial. <i>Lancet Oncology</i> , 2018 , 19, 639-648	21.7	47
750	Gastrointestinal stromal tumors (GIST) presenting in the liver: Diagnostic, prognostic and therapeutic issues. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2018 , 42, e23-e28	2.4	7
749	Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas: A Phase 2 Clinical Trial. <i>JAMA Oncology</i> , 2018 , 4, 93-97	13.4	191
748	The Genomic Grade Index predicts postoperative clinical outcome in patients with soft-tissue sarcoma. <i>Annals of Oncology</i> , 2018 , 29, 459-465	10.3	16
747	Alternative PDGFD rearrangements in dermatofibrosarcomas protuberans without PDGFB fusions. <i>Modern Pathology</i> , 2018 , 31, 1683-1693	9.8	37
746	Outcome of 449 adult patients with rhabdomyosarcoma: an observational ambispective nationwide study. <i>Cancer Medicine</i> , 2018 , 7, 4023-4035	4.8	27
745	A first-in-human study investigating biodistribution, safety and recommended dose of a new radiolabeled MAb targeting FZD10 in metastatic synovial sarcoma patients. <i>BMC Cancer</i> , 2018 , 18, 646	4.8	29
744	Joint adolescent-adult early phase clinical trials to improve access to new drugs for adolescents with cancer: proposals from the multi-stakeholder platform-ACCELERATE. <i>Annals of Oncology</i> , 2018 , 29, 766-771	10.3	44
743	Beliefs and behavior regarding e-cigarettes in a large cross-sectional survey. <i>Preventive Medicine Reports</i> , 2018 , 10, 332-336	2.6	3
742	Efficacy and safety of regorafenib compared to placebo and to post-cross-over regorafenib in advanced non-adipocytic soft tissue sarcoma. <i>European Journal of Cancer</i> , 2018 , 99, 28-36	7.5	9
741	Abstract CT009: Results of a dose- and regimen-finding Phase Ib study of HDM201 in combination with ribociclib in patients with locally advanced or metastatic liposarcoma 2018 ,		5

740	Treatment with Combination of Dabrafenib and Trametinib in Patients with Recurrent/Refractory BRAF V600E-Mutated Hairy Cell Leukemia (HCL). <i>Blood</i> , 2018 , 132, 391-391	2.2	25
739	Final results of ENLIVEN: A global, double-blind, randomized, placebo-controlled, phase 3 study of pexidartinib in advanced tenosynovial giant cell tumor (TGCT).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 11502-11502	2.2	14
738	Results of randomized, placebo (PL)-controlled phase II study evaluating efficacy and safety of regorafenib (REG) in patients (pts) with metastatic osteosarcoma (metOS), on behalf of the French Sarcoma Group (FSG) and Unicancer.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 11504-11504	2.2	2
737	Results of a prospective randomized phase III T-SAR trial comparing trabectedin (T) vs best supportive care (BSC) in patients with pretreated advanced soft tissue sarcoma (ASTS): A French Sarcoma Group (FSG) trial.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 11508-11508	2.2	4
736	Survival impact of surgical management in reference centers for retroperitoneal sarcoma: A nationwide study of FSG-GETO and NETSARC.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 11568-11568	2.2	3
735	Doxorubicin plus dacarbazine (DoDa), doxorubicin plus ifosfamide (DI) or doxorubicin alone (Do) as first line treatment for advanced leiomyosarcoma (LMS): A retrospective study from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 11574-11574	2.2	6
734	Adjuvant gemcitabine plus docetaxel followed by doxorubicin versus observation for uterus-limited, high-grade leiomyosarcoma: A phase III GOG study.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 5505-5505	2.2	5
733	Surrogate endpoints in advanced sarcoma trials: a meta-analysis. <i>Oncotarget</i> , 2018 , 9, 34617-34627	3.3	5
732	Vnn1 pantetheinase limits the Warburg effect and sarcoma growth by rescuing mitochondrial activity. <i>Life Science Alliance</i> , 2018 , 1, e201800073	5.8	10
731	Efficacy of antiangiogenic renal neoplasm with bone metastasis: A mono-institutional study in France.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 610-610	2.2	
730	The 100 Most Influential Papers and Recent Trends in the Field of Gastrointestinal Stromal Tumours: A Bibliometric Analysis. <i>Cureus</i> , 2018 , 10, e2311	1.2	2
729	Compared descriptive analysis of immunologic landscape in soft tissue sarcoma and GIST.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 11517-11517	2.2	
728	Activity and safety of crizotinib in patients with advanced, metastatic alveolar soft part sarcoma (ASPS) with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase 2 trial 90101 CREATE.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 11540-11540	2.2	0
727	PEMBROSARC combination of MK3475 and metronomic cyclophosphamide (mCP) in patients (pts) with advanced sarcomas a multicentre phase II trial with 3 new combination strategies.. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS11587-TPS11587	2.2	1
726	Rare bone sarcoma: A retrospective analysis of 149 adult patients from the French Sarcoma Group.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 11523-11523	2.2	
725	Characteristics and clinical outcomes of French patients diagnosed with advanced soft tissue sarcoma (aSTS) in real-life setting: Data from the European sarcoma biological and clinical data banking (ESBCB).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 11548-11548	2.2	
724	Sarcomas in patients over 90: Natural history and treatment A nationwide study over 6 years.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 11564-11564	2.2	
723	Enjeux et difficultés de la gestion des médicaments oncoeux non intégrés dans la liste en sus pour un hôpital traitant des cancers. <i>Bulletin De L'Académie Nationale De Médecine</i> , 2018 , 202, 1003-1012	0.1	

722	Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study. <i>JAMA Oncology</i> , 2018 , 4, 384-388	13.4	191
721	Presentation and outcome of frequent and rare sarcoma histologic subtypes: A study of 10,262 patients with localized visceral/soft tissue sarcoma managed in reference centers. <i>Cancer</i> , 2018 , 124, 1179-1187	6.4	23
720	Pre- and Postoperative Chemotherapy in Localized Extremity Soft Tissue Sarcoma: A European Organization for Research and Treatment of Cancer Expert Survey. <i>Oncologist</i> , 2018 , 23, 461-467	5.7	19
719	Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma. <i>Oncologist</i> , 2018 , 23, 62-70	5.7	42
718	A phase II, multicenter study of the EZH2 inhibitor tazemetostat in adults (rhabdoid tumor cohort) (NCT02601950). <i>Annals of Oncology</i> , 2018 , 29, viii580-viii581	10.3	7
717	BRAF Inhibition in -Mutant Gliomas: Results From the VE-BASKET Study. <i>Journal of Clinical Oncology</i> , 2018 , 36, 3477-3484	2.2	139
716	Adjuvant Gemcitabine Plus Docetaxel Followed by Doxorubicin Versus Observation for High-Grade Uterine Leiomyosarcoma: A Phase III NRG Oncology/Gynecologic Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2018 , JCO1800454	2.2	44
715	High-Dose Chemotherapy and Blood Autologous Stem-Cell Rescue Compared With Standard Chemotherapy in Localized High-Risk Ewing Sarcoma: Results of Euro-E.W.I.N.G.99 and Ewing-2008. <i>Journal of Clinical Oncology</i> , 2018 , JCO2018782516	2.2	64
714	OA12.05 Vemurafenib in Patients Harboring V600 and Non V600 BRAF Mutations: Final Results of the NSCLC Cohort from the AcS ² Trial. <i>Journal of Thoracic Oncology</i> , 2018 , 13, S348-S349	8.9	7
713	Vemurafenib in Patients With Relapsed Refractory Multiple Myeloma Harboring Mutations: A Cohort of the Histology-Independent VE-BASKET Study. <i>JCO Precision Oncology</i> , 2018 , 2,	3.6	14
712	A phase II, multicenter study of the EZH2 inhibitor tazemetostat in adults (INI1-negative tumors cohort) (NCT02601950). <i>Annals of Oncology</i> , 2018 , 29, viii580	10.3	3
711	Geographical Accessibility of the Referral Networks in France. Intermediate Results from the IGAS Research Program. <i>International Journal of Environmental Research and Public Health</i> , 2018 , 15,	4.6	10
710	Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2018 , 29, iv79-iv95	10.3	223
709	EPIGIST: An observational real-life study on patients with metastatic gastrointestinal stromal tumors receiving imatinib. <i>PLoS ONE</i> , 2018 , 13, e0204117	3.7	5
708	Brain Metastases from Adult Sarcoma: Prognostic Factors and Impact of Treatment. A Retrospective Analysis from the French Sarcoma Group (GSF/GETO). <i>Oncologist</i> , 2018 , 23, 948-955	5.7	9
707	Bcl-xl as the most promising Bcl-2 family member in targeted treatment of chondrosarcoma. <i>Oncogenesis</i> , 2018 , 7, 74	6.6	25
706	The cost-saving effect of centralized histological reviews with soft tissue and visceral sarcomas, GIST, and desmoid tumors: The experiences of the pathologists of the French Sarcoma Group. <i>PLoS ONE</i> , 2018 , 13, e0193330	3.7	21
705	Prognostic and predictive factors for angiosarcoma patients receiving paclitaxel once weekly plus or minus bevacizumab: an ancillary study derived from a randomized clinical trial. <i>BMC Cancer</i> , 2018 , 18, 963	4.8	6

704	Localized Myxofibrosarcomas: Roles of Surgical Margins and Adjuvant Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018 , 102, 399-406	4	12
703	Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2018 , 29, iv68-iv78	10.3	207
702	Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2018 , 29, iv51-iv67	10.3	316
701	Management of sarcoma patients: centralization in reference centers to fragmentation of systemic treatment. <i>Current Opinion in Oncology</i> , 2018 , 30, 240-242	4.2	4
700	Getting up-to-date in the management of soft tissue sarcoma. <i>Future Oncology</i> , 2018 , 14, 3-13	3.6	11
699	NKp30 isoforms and NKp30 ligands are predictive biomarkers of response to imatinib mesylate in metastatic GIST patients. <i>Oncolimmunology</i> , 2017 , 6, e1137418	7.2	37
698	PDL1 expression is a poor-prognosis factor in soft-tissue sarcomas. <i>Oncolimmunology</i> , 2017 , 6, e12781007.2	54	
697	3D absorbed dose distribution estimated by Monte Carlo simulation in radionuclide therapy with a monoclonal antibody targeting synovial sarcoma. <i>EJNMMI Physics</i> , 2017 , 4, 6	4.4	13
696	Advanced chordoma treated by first-line molecular targeted therapies: Outcomes and prognostic factors. A retrospective study of the French Sarcoma Group (GSF/GETO) and the Association des Neuro-Oncologues d'Expression Française (ANOCEF). <i>European Journal of Cancer</i> , 2017 , 79, 119-128	7.5	34
695	Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-ST5 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. <i>Lancet Oncology</i> , 2017 , 18, 812-822	21.7	259
694	Patterns of care and outcomes of patients with METAstatic soft tissue SARComa in a real-life setting: the METASARC observational study. <i>BMC Medicine</i> , 2017 , 15, 78	11.4	91
693	Intensity of recent years in the investigation of soft tissue sarcoma. <i>Future Oncology</i> , 2017 , 13, 3-9	3.6	1
692	Review of past and present clinical cases with a view to future treatment options. <i>Future Oncology</i> , 2017 , 13, 11-28	3.6	2
691	Patterns of care and clinical outcomes in primary oesophageal gastrointestinal stromal tumours (GIST): A retrospective study of the French Sarcoma Group (FSG). <i>European Journal of Surgical Oncology</i> , 2017 , 43, 1110-1116	3.6	8
690	Giant cell tumour of bone in the denosumab era. <i>European Journal of Cancer</i> , 2017 , 77, 75-83	7.5	77
689	Best practices for the management of local-regional recurrent chordoma: a position paper by the Chordoma Global Consensus Group. <i>Annals of Oncology</i> , 2017 , 28, 1230-1242	10.3	108
688	P3.02a-034 Vemurafenib in Patients with Non-Small Cell Lung Cancer (NSCLC) Harboring BRAF Mutation. Preliminary Results of the AcS Trial. <i>Journal of Thoracic Oncology</i> , 2017 , 12, S1182-S1183	8.9	2
687	Description of the immune microenvironment of chondrosarcoma and contribution to progression. <i>Oncolimmunology</i> , 2017 , 6, e1265716	7.2	15

686	Improving treatment results with reference centres for rare cancers: where do we stand?. <i>European Journal of Cancer</i> , 2017 , 77, 90-98	7.5	28
685	REGOSARC: Regorafenib versus placebo in doxorubicin-refractory soft-tissue sarcoma-A quality-adjusted time without symptoms of progression or toxicity analysis. <i>Cancer</i> , 2017 , 123, 2294-2302	6.4	30
684	Advances and controversies in the management of soft tissue sarcomas. <i>Future Oncology</i> , 2017 , 13, 3-11	3.6	6
683	Utility of post-therapy brain surveillance imaging in the detection of primary central nervous system lymphoma relapse. <i>European Journal of Cancer</i> , 2017 , 72, 12-19	7.5	9
682	Sarcoma in 2016: Evolving biological understanding and treatment of sarcomas. <i>Nature Reviews Clinical Oncology</i> , 2017 , 14, 78-80	19.4	10
681	Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE'. <i>Annals of Oncology</i> , 2017 , 28, 3000-3008	10.3	48
680	Long-term efficacy of denosumab in giant cell tumor of bone: Results of an open-label phase 2 study. <i>Annals of Oncology</i> , 2017 , 28, v645-v646	10.3	3
679	Abdominal desmoplastic small round cell tumor without extraperitoneal metastases: Is there a benefit for HIPEC after macroscopically complete cytoreductive surgery?. <i>PLoS ONE</i> , 2017 , 12, e0171639	3.7	39
678	Improved survival using specialized multidisciplinary board in sarcoma patients. <i>Annals of Oncology</i> , 2017 , 28, 2852-2859	10.3	130
677	Ten-Year Progression-Free and Overall Survival in Patients With Unresectable or Metastatic GI Stromal Tumors: Long-Term Analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group Intergroup Phase III Randomized Trial of Imatinib Versus Placebo in Patients With Unresectable or Metastatic GI Stromal Tumors. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1712-1720	2.2	88
676	Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3433-3439	2.2	77
675	Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib. <i>British Journal of Cancer</i> , 2017 , 117, 1278-1285	8.7	25
674	Surgical versus non-surgical approach in primary desmoid-type fibromatosis patients: A nationwide prospective cohort from the French Sarcoma Group. <i>European Journal of Cancer</i> , 2017 , 83, 125-131	7.5	79
673	MDM4 amplification in a case of de-differentiated liposarcoma and in-silico data supporting an oncogenic event alternative to MDM2 amplification in a subset of cases. <i>Histopathology</i> , 2017 , 71, 1019-1023	7.3	9
672	An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma PATients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG). <i>Annals of Oncology</i> , 2017 , 28, 2399-2408	10.3	174
671	Prediction of local and metastatic recurrence in solitary fibrous tumor: construction of a risk calculator in a multicenter cohort from the French Sarcoma Group (FSG) database. <i>Annals of Oncology</i> , 2017 , 28, 1979-1987	10.3	54
670	Treatment patterns and survival in an exhaustive French cohort of pazopanib-eligible patients with metastatic soft tissue sarcoma (STS). <i>BMC Cancer</i> , 2017 , 17, 111	4.8	10
669	Prognostic impact of blood and urinary angiogenic factor levels at diagnosis and during treatment in patients with osteosarcoma: a prospective study. <i>BMC Cancer</i> , 2017 , 17, 419	4.8	2

668	Antiangiogenic effects in patients with progressive desmoplastic small round cell tumor: data from the French national registry dedicated to the use of off-labeled targeted therapy in sarcoma (OUTC's). <i>Clinical Sarcoma Research</i> , 2017 , 7, 10	2.5	11
667	Cost-Effectiveness Analysis of Tyrosine Kinase Inhibitors for Patients with Advanced Gastrointestinal Stromal Tumors. <i>Clinical Drug Investigation</i> , 2017 , 37, 85-94	3.2	2
666	European Journal of Cancer's Biennial report on soft tissue and visceral sarcomas or the rapid evolution of treatment concepts in sarcomas. <i>European Journal of Cancer</i> , 2017 , 70, 83-86	7.5	4
665	Genomic alterations and radioresistance in breast cancer: an analysis of the ProFiLER protocol. <i>Annals of Oncology</i> , 2017 , 28, 2773-2779	10.3	16
664	A Retrospective Multicentric Study of Ewing Sarcoma Family of Tumors in Patients Older Than 50: Management and Outcome. <i>Scientific Reports</i> , 2017 , 7, 17917	4.9	8
663	Expression and role of TYRO3 and AXL as potential therapeutical targets in leiomyosarcoma. <i>British Journal of Cancer</i> , 2017 , 117, 1787-1797	8.7	21
662	Improved overall and progression free survival after surgery in expert sites for sarcoma patients: A nationwide study of FSG-GETO/NETSARC. <i>Annals of Oncology</i> , 2017 , 28, v521	10.3	5
661	Multi-institutional European single-arm phase II trial of pazopanib in advanced malignant/dedifferentiated solitary fibrous tumors (SFT): A collaborative Spanish (GEIS), Italian (ISG), and French (FSG) sarcoma groups study.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 11003-11003	2.2	3
660	Combination of pembrolizumab and metronomic cyclophosphamide in patients with advanced sarcomas and GIST: A French Sarcoma Group phase II trial.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 11053-11053	7	7
659	Trabectedin and radiotherapy in soft-tissue sarcoma (TRASTS) study: An international, prospective, phase I/II trial.. A collaborative Spanish (GEIS), Italian (ISG), and French (FSG) groups study.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 11061-11061	2.2	3
658	International single-arm phase II trial of pazopanib in advanced extraskeletal myxoid chondrosarcoma: A Collaborative Spanish (GEIS), Italian (ISG) and French (FSG) Sarcoma Groups study.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 11062-11062	2.2	3
657	A phase I/II dose escalation and expansion study of cabiralizumab (cabira; FPA-008), an anti-CSF1R antibody, in tenosynovial giant cell tumor (TGCT, diffuse pigmented villonodular synovitis D-PVNS).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 11078-11078	2.2	17
656	Vemurafenib in patients with BRAFV600 mutant glioma: A cohort of the histology-independent VE-basket study.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2004-2004	2.2	1
655	Efficacy of vemurafenib in patients (pts) with non-small cell lung cancer (NSCLC) with BRAFV600 mutation.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 9074-9074	2.2	9
654	Undifferentiated endometrial sarcomas (UES): Results of a French sarcoma group (FSG) retrospective series of 52 patients (pts).. <i>Journal of Clinical Oncology</i> , 2017 , 35, e17109-e17109	2.2	1
653	Routine molecular screening of advanced refractory cancer patients: An analysis of the first 2490 patients of the ProFiLER Study.. <i>Journal of Clinical Oncology</i> , 2017 , 35, LBA100-LBA100	2.2	5
652	A randomized, double-blind, placebo-controlled, phase III study of crenolanib in advanced or metastatic GIST patients bearing a D842V mutation in PDGFRA: The CrenoGIST study.. <i>Journal of Clinical Oncology</i> , 2017 , 35, TPS11080-TPS11080	2.2	9
651	Routine molecular screening of advanced refractory cancer patients: An analysis of the first 2490 patients of the ProFiLER study.. <i>Journal of Clinical Oncology</i> , 2017 , 35, LBA100-LBA100	2.2	10

650	Survival impact of centralization and clinical guidelines for soft tissue sarcoma (A prospective and exhaustive population-based cohort). <i>PLoS ONE</i> , 2017 , 12, e0158406	3.7	46
649	Awareness and misconceptions of colorectal cancer risk factors among laypersons and physicians.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 536-536	2.2	0
648	Post-cross-over activity of regorafenib (RE) in soft tissue sarcoma: Analysis from the REGOSARC trial.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 11052-11052	2.2	2
647	SYNFRIZZ: A first-in-human (FIH) study of a radiolabeled monoclonal antibody (Mab) targeting frizzled homolog 10 (FZD10) in patients (pts) with advanced synovial sarcomas (SyS).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 11054-11054	2.2	1
646	Prognosis of desmoid tumors (DT): A prospective nationwide survey of 771 patients (pts).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 11047-11047	2.2	
645	Expression and prognostic significance of PDGF ligands (A, B, C, and D) and PDGFR (A, B, and L) in soft-tissue sarcomas and GIST.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 11067-11067	2.2	
644	Weekly paclitaxel (WP) +/- bevacizumab (B) in angiosarcoma (AS) patients (pts): Analysis of prognostic/predictive factors from a randomized phase 2 trial.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 11024-11024	2.2	
643	Long-term survival (over 10 years) of inoperable/metastatic GISTs: A retrospective series of 141 patients (pts) of the french sarcoma group (FSG).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 11041-11041	2.2	
642	Outcome of 212 malignant phylloid tumor patients: A retrospective study from the French Sarcoma Group (GSF-GETO).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 11055-11055	2.2	
641	A novel phase I/IIa open-label study of IMM-101 in combination with selected standard of care regimens in patients with metastatic cancer or unresectable cancer at study entry.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e14627-e14627	2.2	
640	Patients with primary localized high-grade sarcomas of the digestive tract excluding GIST : a retrospective study from the French sarcoma group. <i>Acta Gastro-Enterologica Belgica</i> , 2017 , 80, 481-486 ^{0.6}		1
639	The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines. <i>Gastric Cancer</i> , 2016 , 19, 3-14	7.6	225
638	PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue Sarcoma. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3898-3905	2.2	107
637	Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet Oncology, The</i> , 2016 , 17, 1732-1742	21.7	141
636	The nationwide cohort of 26,883 patients with sarcomas treated in NETSARC reference network between 2010 and 2015 in France: major impact of multidisciplinary board presentation prior to 1st treatment. <i>Annals of Oncology</i> , 2016 , 27, vi483	10.3	5
635	sarcoma Full-dose neoadjuvant anthracycline + ifosfamide chemotherapy is associated with a relapse free survival (RFS) and overall survival (OS) benefit in localized high-risk adult soft tissue sarcomas (STS) of the extremities and trunk wall: Interim analysis of a prospective randomized trial. <i>Annals of Oncology</i> , 2016 , 27, vi487	10.3	13
634	Results of a prospective randomized phase III T-SAR trial comparing trabectedin vs best supportive care (BSC) in patients with pretreated advanced soft tissue sarcoma (ASTS). <i>Annals of Oncology</i> , 2016 , 27, vi483	10.3	4
633	Update of the T-DIS randomized phase II trial: Trabectedin rechallenge versus continuation in patients (pts) with advanced soft tissue sarcoma (ASTS). <i>Annals of Oncology</i> , 2016 , 27, vi486	10.3	2

632	Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trial. <i>Lancet Oncology, The</i> , 2016 , 17, 1070-1080	21.7	120
631	L'organisation française en réseau de soins pour la prise en charge des sarcomes. <i>Oncologie</i> , 2016 , 18, 247-256	1	1
630	Equal access to innovative therapies and precision cancer care. <i>Nature Reviews Clinical Oncology</i> , 2016 , 13, 385-93	19.4	34
629	Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. <i>Lancet, The</i> , 2016 , 387, 1629-37	40	445
628	Long-term outcome of molecular subgroups of GIST patients treated with standard-dose imatinib in the BFR14 trial of the French Sarcoma Group. <i>European Journal of Cancer</i> , 2016 , 52, 173-80	7.5	52
627	The value of research collaborations and consortia in rare cancers. <i>Lancet Oncology, The</i> , 2016 , 17, e62-e69	62.7	64
626	Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial. <i>BMC Cancer</i> , 2016 , 16, 22	4.8	43
625	Relationship between imatinib trough concentration and outcomes in the treatment of advanced gastrointestinal stromal tumours in a real-life setting. <i>European Journal of Cancer</i> , 2016 , 57, 31-8	7.5	48
624	The reporting of adverse events in oncology phase III trials: a comparison of the current status versus the expectations of the EORTC members. <i>Annals of Oncology</i> , 2016 , 27, 192-8	10.3	19
623	Small Cell Carcinoma of the Ovary, Hypercalcemic Type: Report of a Bilateral Case in a Teenager Associated with SMARCA4 Germline Mutation. <i>Pediatric and Developmental Pathology</i> , 2016 , 19, 56-60	2.2	10
622	Gastrointestinal stromal tumors in Japanese patients with neurofibromatosis type I. <i>Journal of Gastroenterology</i> , 2016 , 51, 571-8	6.9	31
621	Vemurafenib in Patients with Erdheim-Chester Disease (ECD) and Langerhans Cell Histiocytosis (LCH) Harboring BRAFV600 Mutations: A Cohort of the Histology-Independent VE-Basket Study. <i>Blood</i> , 2016 , 128, 480-480	2.2	3
620	Regorafenib (RE) in liposarcomas (LIPO), leiomyosarcomas (LMS), synovial sarcomas (SYN), and other types of soft-tissue sarcomas (OTS): Results of an international, double-blind, randomized, placebo (PL) controlled phase II trial.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 11003-11003	2.2	4
619	Integrative assessment of expression and prognostic value of PDL1, IDO, and kynurenine in 371 primary soft tissue sarcomas with genomic complexity.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 11008-11008	2.2	7
618	Improved sarcoma management in a national network of reference centers: Analysis of the NetSarc network on 13,454 patients treated between 2010 and 2014.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 11013-11013	13.3	8
617	Patterns of care and outcome of patients (pts) with metastatic soft-tissue sarcoma (STS) according to histological subtype and treatment setting: The METASTAR study.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 11014-11014	2.2	4
616	Subtype-specific activity in liposarcoma (LPS) patients (pts) from a phase 3, open-label, randomized study of eribulin (ERI) versus dacarbazine (DTIC) in pts with advanced LPS and leiomyosarcoma (LMS).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 11037-11037	2.2	5
615	Final overall survival (OS) analysis with modeling of crossover impact in the phase III GRID trial of regorafenib vs placebo in advanced gastrointestinal stromal tumors (GIST).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 156-156	2.2	6

614	Circulating vascular endothelial growth factor (VEGF) as predictive factor of progression-free survival in patients with advanced chordoma receiving sorafenib: an analysis from a phase II trial of the french sarcoma group (GSF/GETO). <i>Oncotarget</i> , 2016 , 7, 73984-73994	3.3	18
613	Ewing sarcoma Family of Tumors in Older Patients (EFyTOP): Management and outcome of Ewing sarcoma family of tumors (EFTs) in patients older than 50 years.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 11023-11023	2.2	
612	First things first: Prevention, screening or care?. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1550-1550	2.2	
611	Molecular targeted therapies (MTT) in advanced chordoma (AC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 11020-11020	2.2	0
610	Biomarker-driven access to vemurafenib in BRAF-positive cancers: Second study of the French National AcS'Program.. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS11620-TPS11620	2.2	1
609	Impact of the Use of Polymerase Chain Reaction for the Diagnosis and Management of Pneumocystis Jirovecii Pneumoniae in a Retrospective Cohort of Patients with Lymphoid Malignancies. <i>Blood</i> , 2016 , 128, 688-688	2.2	
608	Cost of treatment in patients with metastatic soft tissue sarcoma who respond favourably to chemotherapy. The SARcoma treatment and Burden of Illness in North America and Europe (SABINE) study. <i>European Journal of Cancer Care</i> , 2016 , 25, 466-77	2.4	4
607	Adjuvant imatinib treatment in gastrointestinal stromal tumor: which risk stratification criteria and for how long? A case report. <i>Anti-Cancer Drugs</i> , 2016 , 27, 71-5	2.4	7
606	A phase I study of the MDM2 inhibitor AMG 232 in patients with advanced p53 wild type (p53WT) solid tumors or multiple myeloma. <i>European Journal of Cancer</i> , 2016 , 69, S34	7.5	3
605	Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial. <i>Lancet Oncology, The</i> , 2016 , 17, 632-41	21.7	76
604	Aggregated adverse-events outcomes in oncology phase III reports: A systematic review. <i>European Journal of Cancer</i> , 2016 , 52, 26-32	7.5	3
603	Outcome of uterine sarcoma patients treated with pazopanib: A retrospective analysis based on two European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) clinical trials 62043 and 62072. <i>Gynecologic Oncology</i> , 2016 , 142, 89-94	4.9	38
602	Impact of chemotherapy in uterine sarcoma (UtS): review of 13 clinical trials from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) involving advanced/metastatic UtS compared to other soft tissue sarcoma (STS) patients treated with first line chemotherapy. <i>Gynecologic Oncology</i> , 2016 , 142, 95-101	4.9	13
601	Management of desmoid tumours: A nationwide survey of labelled reference centre networks in France. <i>European Journal of Cancer</i> , 2016 , 58, 90-6	7.5	72
600	Current status and unanswered questions on the use of Denosumab in giant cell tumor of bone. <i>Clinical Sarcoma Research</i> , 2016 , 6, 15	2.5	64
599	Monogenic and polygenic determinants of sarcoma risk: an international genetic study. <i>Lancet Oncology, The</i> , 2016 , 17, 1261-71	21.7	121
598	Management of Recurrent Retroperitoneal Sarcoma (RPS) in the Adult: A Consensus Approach from the Trans-Atlantic RPS Working Group. <i>Annals of Surgical Oncology</i> , 2016 , 23, 3531-3540	3.1	82
597	Management of Gastrointestinal Stromal Tumour: Current Practices and Visions for the Future. <i>Oncology</i> , 2015 , 89, 1-13	3.6	22

596	A phase IIb multicentre study comparing the efficacy of trabectedin to doxorubicin in patients with advanced or metastatic untreated soft tissue sarcoma: the TRUSTS trial. <i>European Journal of Cancer</i> , 2015 , 51, 1312-20	7.5	53
595	Key Issues in the Clinical Management of Gastrointestinal Stromal Tumors: An Expert Discussion. <i>Oncologist</i> , 2015 , 20, 823-30	5.7	23
594	Rare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers: a European consensus position paper. <i>Annals of Oncology</i> , 2015 , 26, 300-6	10.3	51
593	CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study. <i>Lancet Oncology, The</i> , 2015 , 16, 949-56	21.7	228
592	Guidelines for time-to-event end point definitions in sarcomas and gastrointestinal stromal tumors (GIST) trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials) <i>Annals of Oncology</i> , 2015 , 26, 865-872	10.3	34
591	Hemorrhage due to radiation-induced sarcoma of the mandible: treatment with percutaneous cryotherapy. <i>Diagnostic and Interventional Imaging</i> , 2015 , 96, 407-9	5.4	
590	Nilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): a randomised phase 3 trial. <i>Lancet Oncology, The</i> , 2015 , 16, 550-60	21.7	79
589	Ombrabulin plus cisplatin versus placebo plus cisplatin in patients with advanced soft-tissue sarcomas after failure of anthracycline and ifosfamide chemotherapy: a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2015 , 16, 531-40	21.7	42
588	Prostate cancer screening: contrasting trends. <i>Cancer Causes and Control</i> , 2015 , 26, 949-52	2.8	8
587	Study protocol of REGOSARC trial: activity and safety of regorafenib in advanced soft tissue sarcoma: a multinational, randomized, placebo-controlled, phase II trial. <i>BMC Cancer</i> , 2015 , 15, 127	4.8	20
586	Giant cell tumors of bone 2015 , 437-445		1
585	ELYPSE-7: a randomized placebo-controlled phase IIa trial with CYT107 exploring the restoration of CD4+ lymphocyte count in lymphopenic metastatic breast cancer patients. <i>Annals of Oncology</i> , 2015 , 26, 1353-62	10.3	28
584	Assessing the multimodal management of advanced solitary fibrous tumors of the pleura in a routine practice setting. <i>Journal of Thoracic Oncology</i> , 2015 , 10, 309-15	8.9	18
583	First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)--a systematic review and individual patient data meta-analysis. <i>Annals of Oncology</i> , 2015 , 26, 1305-13	10.3	106
582	Paclitaxel Given Once Per Week With or Without Bevacizumab in Patients With Advanced Angiosarcoma: A Randomized Phase II Trial. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2797-802	2.2	117
581	Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO). <i>Annals of Oncology</i> , 2015 , 26, 2168-73	10.3	69
580	Thymic epithelial tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2015 , 26 Suppl 5, v40-55	10.3	208
579	Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. <i>New England Journal of Medicine</i> , 2015 , 373, 726-36	59.2	1172

578	SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas. <i>Nature Genetics</i> , 2015 , 47, 1200-5	36.3	170
577	Nilotinib versus imatinib for GIST - Authors' reply. <i>Lancet Oncology</i> , 2015 , 16, e311-2	21.7	
576	The GOLD ReGISTry: a Global, Prospective, Observational Registry Collecting Longitudinal Data on Patients with Advanced and Localised Gastrointestinal Stromal Tumours. <i>European Journal of Cancer</i> , 2015 , 51, 2423-33	7.5	25
575	Etoposide and carbo-or cisplatin combination therapy in refractory or relapsed Ewing sarcoma: a large retrospective study. <i>Pediatric Blood and Cancer</i> , 2015 , 62, 40-4	3	14
574	12LBA Biomarker-driven access to crizotinib in ALK, MET or ROS1 positive (+) malignancies in adults and children: The French national AcSe Program. <i>European Journal of Cancer</i> , 2015 , 51, S715	7.5	3
573	Impact of gender on efficacy and acute toxicity of alkylating agent -based chemotherapy in Ewing sarcoma: secondary analysis of the Euro-Ewing99-R1 trial. <i>European Journal of Cancer</i> , 2015 , 51, 2453-64	7.5	11
572	Detection of tumor ALK status in neuroblastoma patients using peripheral blood. <i>Cancer Medicine</i> , 2015 , 4, 540-50	4.8	55
571	Prediction of desmoid tumor progression using miRNA expression profiling. <i>Cancer Science</i> , 2015 , 106, 650-5	6.9	9
570	Targeting tumor-associated macrophages in cancer patients. <i>Annals of Oncology</i> , 2015 , 26, ii12	10.3	
569	Off-label use of targeted therapies in osteosarcomas: data from the French registry OUTC'S (Observatoire de l'Utilisation des Thérapies Ciblées dans les Sarcomes). <i>BMC Cancer</i> , 2015 , 15, 854	4.8	21
568	Efficacy of trabectedin in malignant solitary fibrous tumors: a retrospective analysis from the French Sarcoma Group. <i>BMC Cancer</i> , 2015 , 15, 700	4.8	31
567	KIT exon 10 variant (c.1621 A > C) single nucleotide polymorphism as predictor of GIST patient outcome. <i>BMC Cancer</i> , 2015 , 15, 780	4.8	11
566	Health-related quality-of-life results from PALETTE: A randomized, double-blind, phase 3 trial of pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or after prior chemotherapy-a European Organization for research and treatment of cancer soft tissue and bone sarcoma group global network study (EORTC 62072). <i>Cancer</i> , 2015 , 121, 2933-41	6.4	62
565	Primary cutaneous and subcutaneous Ewing sarcoma. <i>Pediatric Blood and Cancer</i> , 2015 , 62, 1555-61	3	17
564	Challenges in the implementation of trastuzumab biosimilars: an expert panel's recommendations. <i>Anti-Cancer Drugs</i> , 2015 , 26, 1009-16	2.4	9
563	Lung cancer risks, beliefs and healthcare access among the underprivileged. <i>European Journal of Cancer Prevention</i> , 2015 , 24 Suppl, S82-6	2	6
562	Cancer screening in France: third edition of the EDIFICE survey. <i>European Journal of Cancer Prevention</i> , 2015 , 24 Suppl, S68-72	2	6
561	Trabectedin in advanced synovial sarcomas: a multicenter retrospective study from four European institutions and the Italian Rare Cancer Network. <i>Anti-Cancer Drugs</i> , 2015 , 26, 678-81	2.4	33

560	Breast cancer screening controversy: too much or not enough?. <i>European Journal of Cancer Prevention</i> , 2015 , 24 Suppl, S73-6	2	5
559	Consensus nomenclature for CD8 T cell phenotypes in cancer. <i>OncoImmunology</i> , 2015 , 4, e998538	7.2	101
558	Eight years tumor control with pazopanib for a metastatic resistant epithelioid hemangioendothelioma. <i>Clinical Sarcoma Research</i> , 2015 , 5, 12	2.5	26
557	Trabectedin in patients with advanced soft tissue sarcoma: a retrospective national analysis of the French Sarcoma Group. <i>European Journal of Cancer</i> , 2015 , 51, 742-50	7.5	70
556	Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial. <i>Lancet Oncology, The</i> , 2015 , 16, 312-9	21.7	67
555	Treating metastatic sarcomas locally: a paradox, a rationale, an evidence?. <i>Critical Reviews in Oncology/Hematology</i> , 2015 , 95, 62-77	7	10
554	Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma	2.2	102
553	Gene Expression Profiling of Desmoid Tumors by cDNA Microarrays and Correlation with Progression-Free Survival. <i>Clinical Cancer Research</i> , 2015 , 21, 4194-200	12.9	31
552	Disequilibrium of BMP2 levels in the breast stem cell niche launches epithelial transformation by overamplifying BMPR1B cell response. <i>Stem Cell Reports</i> , 2015 , 4, 239-54	8	40
551	Clinical trial designs for rare diseases: studies developed and discussed by the International Rare Cancers Initiative. <i>European Journal of Cancer</i> , 2015 , 51, 271-81	7.5	80
550	Building a global consensus approach to chordoma: a position paper from the medical and patient community. <i>Lancet Oncology, The</i> , 2015 , 16, e71-83	21.7	269
549	Vemurafenib (VEM) in Relapsed Refractory Multiple Myeloma Harboring BRAFV600 Mutations (V600m): A Cohort of the Histology-Independent VE-Basket Study. <i>Blood</i> , 2015 , 126, 4263-4263	2.2	9
548	Cancer screening in France: Reaching a plateau? New edition of an iterative nationwide survey.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1565-1565	2.2	2
547	Phase I study of RG7155, a novel anti-CSF1R antibody, in patients with advanced/metastatic solid tumors.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3005-3005	2.2	22
546	Randomized, open-label, multicenter, phase III study of eribulin versus dacarbazine in patients (pts) with leiomyosarcoma (LMS) and adipocytic sarcoma (ADI).. <i>Journal of Clinical Oncology</i> , 2015 , 33, LBA10502-LBA10502	2.2	16
545	An updated overall survival analysis with correction for protocol-planned crossover of the international, phase III, randomized, placebo-controlled trial of regorafenib in advanced gastrointestinal stromal tumors after failure of imatinib and sunitinib (GRID).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1110-1110	2.2	6
544	Genomic alterations to predict response to irinotecan-based chemotherapy in metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 586-586	2.2	1
543	Diagnostic Accuracy of PET/CT-Guided Percutaneous Biopsies for Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1 Patients. <i>PLoS ONE</i> , 2015 , 10, e0138386	3.7	26

542	A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer. <i>Oncotarget</i> , 2015 , 6, 14139-52	3.3	19
541	The sum of gains and losses of genes encoding the protein tyrosine kinase targets predicts response to multi-kinase inhibitor treatment: Characterization, validation, and prognostic value. <i>Oncotarget</i> , 2015 , 6, 26388-99	3.3	8
540	Social stratification, risk factor prevalence and cancer screening attendance. <i>European Journal of Cancer Prevention</i> , 2015 , 24 Suppl, S77-81	2	6
539	Identification des voies de signalisations essentielles à la progression tumorale dans les sarcomes : un modèle pour les interactions cellules tumorales et stroma. <i>Bulletin De L'Académie Nationale De Médecine</i> , 2015 , 199, 41-61	0.1	
538	A randomized, open-label, Phase II trial evaluating the clinical benefit of a maintenance treatment targeting tumor molecular alterations in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2015 , 33, TPS2622-TPS2622	2.2	
537	Combination of Rituximab with Chemotherapy Improved Outcome of Newly Diagnosed Primary CNS Lymphoma: A Retrospective Study of 209 Unselected Patients Referred to a Single Institution. <i>Blood</i> , 2015 , 126, 1544-1544	2.2	
536	A Phase II multicenter, open-label, clinical and pharmacokinetic trial of PM00104 in patients with advanced Ewing Family of Tumors. <i>Investigational New Drugs</i> , 2014 , 32, 171-7	4.3	9
535	Retroperitoneal sarcomas: patterns of care in advanced stages, prognostic factors and focus on main histological subtypes: a multicenter analysis of the French Sarcoma Group. <i>Annals of Oncology</i> , 2014 , 25, 730-734	10.3	38
534	Retroperitoneal sarcomas: patterns of care at diagnosis, prognostic factors and focus on main histological subtypes: a multicenter analysis of the French Sarcoma Group. <i>Annals of Oncology</i> , 2014 , 25, 735-742	10.3	102
533	Economic Impact of Centralized Histological Reviews in Patients with Sarcoma, Gist, and Desmoid Tumors. <i>Value in Health</i> , 2014 , 17, A624	3.3	2
532	Pazopanib in advanced desmoplastic small round cell tumours: a multi-institutional experience. <i>Clinical Sarcoma Research</i> , 2014 , 4, 7	2.5	38
531	Primary localized rectal/pararectal gastrointestinal stromal tumors: results of surgical and multimodal therapy from the French Sarcoma group. <i>BMC Cancer</i> , 2014 , 14, 156	4.8	25
530	Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas. <i>European Journal of Cancer</i> , 2014 , 50, 1137-47	7.5	85
529	International expert opinion on patient-tailored management of soft tissue sarcomas. <i>European Journal of Cancer</i> , 2014 , 50, 679-89	7.5	30
528	Primary cardiac sarcomas: a retrospective study of the French Sarcoma Group. <i>European Journal of Cancer</i> , 2014 , 50, 128-36	7.5	80
527	Targeted imaging of (v)β3 expressing sarcoma tumor cells in vivo in pre-operative setting using near infrared: a potential tool to reduce incomplete surgical resection. <i>Bone</i> , 2014 , 62, 71-8	4.7	10
526	Adherence to imatinib therapy in patients with gastrointestinal stromal tumors. <i>Cancer Treatment Reviews</i> , 2014 , 40, 242-7	14.4	26
525	Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. <i>Cancer Cell</i> , 2014 , 25, 846-59	24.3	817

524	Conservative surgery vs. duodeneopancreatectomy in primary duodenal gastrointestinal stromal tumors (GIST): a retrospective review of 114 patients from the French sarcoma group (FSG). <i>European Journal of Surgical Oncology</i> , 2014 , 40, 1369-75	3.6	22
523	Targeted polytherapy in small cell sarcoma and its association with doxorubicin. <i>Molecular Oncology</i> , 2014 , 8, 1458-68	7.9	7
522	Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. <i>Lancet Oncology</i> , 2014 , 15, 415-23	21.7	629
521	Oncogènes, gènes suppresseurs de tumeurs, et aneuploïdie : la somme de toutes les nuances. <i>Bulletin Du Cancer</i> , 2014 , 101, 340	2.4	
520	Territorial inequalities in management and conformity to clinical guidelines for sarcoma patients: an exhaustive population-based cohort analysis in the Rhône-Alpes region. <i>International Journal of Clinical Oncology</i> , 2014 , 19, 744-52	4.2	24
519	Classification of current anticancer immunotherapies. <i>Oncotarget</i> , 2014 , 5, 12472-508	3.3	301
518	Zoledronate Does not Reduce the Risk of Treatment Failure in Osteosarcoma: Results of the French Multicentre Os2006 Randomised Trial. <i>Annals of Oncology</i> , 2014 , 25, iv494	10.3	3
517	Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2014 , 25 Suppl 3, iii102-12	10.3	376
516	Efficacy and safety of trabectedin as an early treatment for advanced or metastatic liposarcoma and leiomyosarcoma. <i>Future Oncology</i> , 2014 , 10, 59-68	3.6	20
515	Prognostic factors and impact of adjuvant treatments on local and metastatic relapse of soft-tissue sarcoma patients in the competing risks setting. <i>Cancer</i> , 2014 , 120, 3361-9	6.4	50
514	Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2014 , 25 Suppl 3, iii21-6	10.3	275
513	Optimizing treatment outcomes with regorafenib: personalized dosing and other strategies to support patient care. <i>Oncologist</i> , 2014 , 19, 669-80	5.7	53
512	The off-label use of targeted therapies in sarcomas: the OUTC'S program. <i>BMC Cancer</i> , 2014 , 14, 870	4.8	19
511	Dsh homolog DVL3 mediates resistance to IGFIR inhibition by regulating IGF-RAS signaling. <i>Cancer Research</i> , 2014 , 74, 5866-77	10.1	20
510	Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: a randomized controlled open-label trial. <i>Annals of Oncology</i> , 2014 , 25, 1762-1769	10.3	54
509	Cost of Discordant Diagnoses in Sarcoma, Gist, and Desmoid Tumors in France: Results From the RREPS (Reseau De Reference En Pathologie Des Sarcomes) Network. <i>Value in Health</i> , 2014 , 17, A95-A96	3.3	4
508	Going further in the knowledge of Yondelis® ; what's new in daily clinical practice?. <i>Future Oncology</i> , 2014 , 10, s13-7	3.6	2
507	A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: results of a Sarcoma Alliance for Research Through Collaboration study. <i>Cancer</i> , 2014 , 120, 2448-56	6.4	133

506	Going further in the knowledge of Yondelis® ; what's new in clinical trials?. <i>Future Oncology</i> , 2014 , 10, s7-s12	3.6	2
505	The histone deacetylase inhibitor panobinostat is active in patients with advanced pretreated ovarian sex-cord tumors. <i>Annals of Oncology</i> , 2014 , 25, 1074-5	10.3	3
504	Long-term recurrence of soft tissue sarcomas: prognostic factors and implications for prolonged follow-up. <i>Cancer</i> , 2014 , 120, 3003-6	6.4	30
503	Response to chemotherapy is not related to chromosome instability in synovial sarcoma. <i>Annals of Oncology</i> , 2014 , 25, 2267-2271	10.3	23
502	Doxorubicin-based adjuvant chemotherapy in soft tissue sarcoma: pooled analysis of two STBSG-EORTC phase III clinical trials. <i>Annals of Oncology</i> , 2014 , 25, 2425-2432	10.3	96
501	Tumor genotype is an independent prognostic factor in primary gastrointestinal stromal tumors of gastric origin: a european multicenter analysis based on ConticaGIST. <i>Clinical Cancer Research</i> , 2014 , 20, 6105-16	12.9	96
500	Sunitinib in combination with trastuzumab for the treatment of advanced breast cancer: activity and safety results from a phase II study. <i>BMC Cancer</i> , 2014 , 14, 166	4.8	20
499	Transferability of health cost evaluation across locations in oncology: cluster and principal component analysis as an explorative tool. <i>BMC Health Services Research</i> , 2014 , 14, 537	2.9	7
498	The clinician's perspective on sarcoma pathology reporting: impact on treatment decisions?. <i>Pathology</i> , 2014 , 46, 121-5	1.6	6
497	Adjuvant radiotherapy for extremity and trunk wall atypical lipomatous tumor/well-differentiated LPS (ALT/WD-LPS): a French Sarcoma Group (GSF-GETO) study. <i>Annals of Oncology</i> , 2014 , 25, 1854-1860	10.3	27
496	Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2014 , 25 Suppl 3, iii113-23	10.3	179
495	Sporadic desmoid-type fibromatosis: a stepwise approach to a non-metastasising neoplasm--a position paper from the Italian and the French Sarcoma Group. <i>Annals of Oncology</i> , 2014 , 25, 578-583	10.3	121
494	Impact of KIT exon 10 M541L allelic variant on the response to imatinib in aggressive fibromatosis: analysis of the desminib series by competitive allele specific Taqman PCR technology. <i>BMC Cancer</i> , 2014 , 14, 632	4.8	12
493	Brastallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: an European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group randomised phase II and pharmacogenetic study. <i>European Journal of Cancer</i> , 2014 , 50, 368-36	7.5	28
492	Low level of baseline circulating VEGF-A is associated with better outcome in patients with vascular sarcomas receiving sorafenib: an ancillary study from a phase II trial. <i>Targeted Oncology</i> , 2014 , 9, 273-7	5	18
491	ANGIOTAX-PLUS trial: A randomized phase II trial assessing the activity of weekly paclitaxel (WP) plus or minus bevacizumab (B) in advanced angiosarcoma (AS).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 10501-10501	2.2	7
490	Phase 1 study of RG7155, a novel anti-CSF1R antibody, in patients with locally advanced pigmented villonodular synovitis (PVNS).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 10504-10504	2.2	5
489	Results of the prospective T-DIS randomized phase II trial comparing interruption versus continuation of trabectedin after six cycles of treatment in patients (pts) with advanced soft tissue sarcoma (ASTS).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 10523-10523	2.2	2

488	Correlation of KIT and PDGFRA mutational status with clinical benefit in patients (pts) with gastrointestinal stromal tumor (GIST) treated with sunitinib (SU) in a worldwide treatment-use (TU) trial.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 10549-10549	2.2	1
487	Pazopanib in uterine sarcoma (UTS): Review of two European Organisation for Research and Treatment of Cancer (EORTC) and GSK clinical trials 62043 and 62072 on pazopanib for soft tissue sarcoma (STS).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 10579-10579	2.2	2
486	Vulnerable populations and overconfidence in cancer screening.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1574-1574	2.2	2
485	VE-BASKET, a first-in-kind, phase II, histology-independent Basket study of vemurafenib (VEM) in nonmelanoma solid tumors harboring BRAF V600 mutations (V600m).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2533-2533	2.2	8
484	Phase 1 dose escalation, food effect, and biomarker study of RG7388, a more potent second-generation MDM2 antagonist, in patients (pts) with solid tumors.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2535-2535	2.2	27
483	Identifying actionable targets in advanced cancer patients: Preliminary results from the Profiler program.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2621-2621	2.2	1
482	VE-BASKET, a Simon 2-stage adaptive design, phase II, histology-independent study in nonmelanoma solid tumors harboring BRAF V600 mutations (V600m): Activity of vemurafenib (VEM) with or without cetuximab (CTX) in colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3518-3518	2.2	17
481	Breast cancer screening controversy: Impact on other cancer screening programs.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e12507-e12507	2.2	0
480	Biomarker-driven access to crizotinib in ALK-, MET-, or ROS1-positive malignancies in adults and children: Feasibility of the French National Acs Program.. <i>Journal of Clinical Oncology</i> , 2014 , 32, TPS2647-TPS2647	2.2	27
479	Utility of 18F-FDG PET with a semi-quantitative index in the detection of sarcomatous transformation in patients with neurofibromatosis type 1. <i>PLoS ONE</i> , 2014 , 9, e85954	3.7	44
478	A four-arm randomized phase II trial with NGR-hTNF given at low or high dose with or without doxorubicin in soft tissue sarcomas (STS).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 10525-10525	2.2	
477	Improved survival in an exhaustive population based on a cohort of liposarcoma (LPS) patients treated in expert centers according to clinical practice guidelines (CPG'S): Experience from Rhone Alpes (RA) region.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 10581-10581	2.2	
476	ELYPSE-7: A randomized, placebo-controlled, phase 2a study evaluating the impact of IL-7 on CD4 count, hematological toxicity, and tumor progression in metastatic breast cancer (MBC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3033-3033	2.2	
475	The Efficacy of Vemurafenib in Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Preliminary Results from VE-Basket Study. <i>Blood</i> , 2014 , 124, 635-635	2.2	2
474	Updated Results Confirm Favorable Outcome of Immunocompetent Patients with Primary CNS Lymphoma Treated By C5R Protocol in Combination with Intravenous Rituximab and Intrathecal Liposomal Cytarabine: A Multicentric Prospective Phase 2 Study of the Lymphoma Study Association (LYSA). <i>Blood</i> , 2014 , 124, 3060-3060	2.2	
473	Response to imatinib in villonodular pigmented synovitis (PVNS) resistant to nilotinib. <i>Clinical Sarcoma Research</i> , 2013 , 3, 8	2.5	29
472	Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. <i>Lancet Oncology</i> , 2013 , 14, 901-8	21.7	389
471	Outcome of patients with advanced solitary fibrous tumors: the Centre Lön Bfard experience. <i>BMC Cancer</i> , 2013 , 13, 109	4.8	49

470	Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use program. <i>BMC Cancer</i> , 2013 , 13, 64	4.8	55
469	Autocrine role for Gas6 with Tyro3 and Axl in leiomyosarcomas. <i>Targeted Oncology</i> , 2013 , 8, 261-9	5	9
468	Prognostic factors in adolescents and young adults (AYA) with high risk soft tissue sarcoma (STS) treated by adjuvant chemotherapy: a study based on pooled European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62771 and 62931. <i>European Journal of Cancer</i> , 2013 , 49, 449-56	7.5	32
467	Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors. <i>Cancer Research</i> , 2013 , 73, 3499-510	10.1	215
466	Breast cancer-derived transforming growth factor- β and tumor necrosis factor- α compromise interferon- γ production by tumor-associated plasmacytoid dendritic cells. <i>International Journal of Cancer</i> , 2013 , 133, 771-8	7.5	65
465	Advanced chondrosarcomas: role of chemotherapy and survival. <i>Annals of Oncology</i> , 2013 , 24, 2916-22	10.3	142
464	A dose-escalating phase I of imatinib mesylate with fixed dose of metronomic cyclophosphamide in targeted solid tumours. <i>British Journal of Cancer</i> , 2013 , 109, 2574-8	8.7	23
463	Diagnosis, prognosis and treatment of patients with gastrointestinal stromal tumour (GIST) and germline mutation of KIT exon 13. <i>European Journal of Cancer</i> , 2013 , 49, 2531-41	7.5	29
462	Tumor promotion by intratumoral plasmacytoid dendritic cells is reversed by TLR7 ligand treatment. <i>Cancer Research</i> , 2013 , 73, 4629-40	10.1	132
461	Sorafenib in patients with progressive epithelioid hemangioendothelioma: a phase 2 study by the French Sarcoma Group (GSF/GETO). <i>Cancer</i> , 2013 , 119, 2639-44	6.4	69
460	An unusual giant cell tumor of the thyroid: case report and review of the literature. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013 , 98, 1-6	5.6	45
459	Patients with metastatic breast cancer leading to CD4+ T cell lymphopaenia have poor outcome. <i>European Journal of Cancer</i> , 2013 , 49, 1673-82	7.5	30
458	Effects of endoplasmic reticulum stressors on maturation and signaling of hemizygous and heterozygous wild-type and mutant forms of KIT. <i>Molecular Oncology</i> , 2013 , 7, 323-33	7.9	9
457	CD4 lymphopenia to identify end-of-life metastatic cancer patients. <i>European Journal of Cancer</i> , 2013 , 49, 1080-9	7.5	25
456	Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2013 , 381, 295-302	40	908
455	Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysis. <i>European Journal of Cancer</i> , 2013 , 49, 1027-31	7.5	61
454	Trabectedin's contribution to the treatment of sarcomas. <i>Expert Review of Anticancer Therapy</i> , 2013 , 13, 3-9	3.5	1
453	Personalized medicine in oncology: where have we come from and where are we going?. <i>Pharmacogenomics</i> , 2013 , 14, 931-9	2.6	36

452	An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours. <i>European Journal of Cancer</i> , 2013 , 49, 3219-28	7.5	66
451	New fronts in the adjuvant treatment of GIST. <i>Cancer Chemotherapy and Pharmacology</i> , 2013 , 72, 715-23	3.5	7
450	High frequency of MYC gene amplification is a common feature of radiation-induced sarcomas. Further results from EORTC STBSG TL 01/01. <i>Genes Chromosomes and Cancer</i> , 2013 , 52, 93-8	5	25
449	Evidence of time-dependent prognostic factors predicting early death but not long-term outcome in primary CNS lymphoma: a study of 91 patients. <i>Hematological Oncology</i> , 2013 , 31, 57-64	1.3	13
448	A decade of change in the treatment of advanced soft tissue sarcoma. <i>Expert Review of Anticancer Therapy</i> , 2013 , 13, 1-2	3.5	4
447	Influence of imatinib interruption and rechallenge on the residual disease in patients with advanced GIST: results of the BFR14 prospective French Sarcoma Group randomised, phase III trial. <i>Annals of Oncology</i> , 2013 , 24, 1087-93	10.3	64
446	Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors. <i>Annals of Oncology</i> , 2013 , 24, 784-91	10.3	37
445	Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy. <i>Annals of Oncology</i> , 2013 , 24, 537-542	10.3	31
444	Primary leptomeningeal lymphoma: International Primary CNS Lymphoma Collaborative Group report. <i>Neurology</i> , 2013 , 81, 1690-6	6.5	53
443	Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy. <i>Journal of Clinical Oncology</i> , 2013 , 31, 2485-92	2.2	180
442	Correlation between overall survival and growth modulation index in pre-treated sarcoma patients: a study from the French Sarcoma Group. <i>Annals of Oncology</i> , 2013 , 24, 2681-2685	10.3	13
441	Advanced soft-tissue sarcoma in elderly patients: patterns of care and survival. <i>Annals of Oncology</i> , 2013 , 24, 1924-1930	10.3	34
440	Impact of molecular analysis on the final sarcoma diagnosis: a study on 763 cases collected during a European epidemiological study. <i>American Journal of Surgical Pathology</i> , 2013 , 37, 1259-68	6.7	40
439	GDC-0449 in patients with advanced chondrosarcomas: a French Sarcoma Group/US and French National Cancer Institute Single-Arm Phase II Collaborative Study. <i>Annals of Oncology</i> , 2013 , 24, 2922-6	10.3	60
438	Genetic profiling identifies two classes of soft-tissue leiomyosarcomas with distinct clinical characteristics. <i>Clinical Cancer Research</i> , 2013 , 19, 1190-6	12.9	39
437	Results of a phase II pilot study of moderate dose radiotherapy for inoperable desmoid-type fibromatosis--an EORTC STBSG and ROG study (EORTC 62991-22998). <i>Annals of Oncology</i> , 2013 , 24, 2672-2676	10.3	94
436	ICOS is associated with poor prognosis in breast cancer as it promotes the amplification of immunosuppressive CD4 T cells by plasmacytoid dendritic cells. <i>Oncol Immunology</i> , 2013 , 2, e23185	7.2	43
435	Trabectedin is a feasible treatment for soft tissue sarcoma patients regardless of patient age: a retrospective pooled analysis of five phase II trials. <i>British Journal of Cancer</i> , 2013 , 109, 1717-24	8.7	49

434	A phase II trial of panobinostat in patients with advanced pretreated soft tissue sarcoma. A study from the French Sarcoma Group. <i>British Journal of Cancer</i> , 2013 , 109, 909-14	8.7	45
433	Optimizing tyrosine kinase inhibitor therapy in gastrointestinal stromal tumors: exploring the benefits of continuous kinase suppression. <i>Oncologist</i> , 2013 , 18, 1192-9	5.7	13
432	Plasmacytoid dendritic cells deficient in IFN γ production promote the amplification of FOXP3 regulatory T cells and are associated with poor prognosis in breast cancer patients. <i>OncoImmunology</i> , 2013 , 2, e22338	7.2	39
431	Molecular characterisation of gastrointestinal stromal tumours in a South African population. <i>Oncology Letters</i> , 2013 , 5, 155-160	2.6	6
430	Abstract LB-295: Detection of oncogenic kinase mutations in circulating plasma DNA and correlation with clinical benefit in the phase III GRID study of regorafenibvsplacebo in TKI-refractory metastatic GIST. 2013 ,		4
429	Utility Of Post Therapy Brain Surveillance Imaging In The Detection Of Primary CNS Lymphoma (PCNSL) Relapse. <i>Blood</i> , 2013 , 122, 933-933	2.2	1
428	Imatinib failure-free survival (IFS) in patients with localized gastrointestinal stromal tumors (GIST) treated with adjuvant imatinib (IM): The EORTC/AGITG/FSG/GEIS/ISG randomized controlled phase III trial.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 10500-10500	2.2	24
427	Phase III trial of nilotinib versus imatinib as first-line targeted therapy of advanced gastrointestinal stromal tumors (GIST).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 10501-10501	2.2	7
426	Mutational analysis of plasma DNA from patients (pts) in the phase III GRID study of regorafenib (REG) versus placebo (PL) in tyrosine kinase inhibitor (TKI)-refractory GIST: Correlating genotype with clinical outcomes.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 10503-10503	2.2	20
425	Phase Ib study of RG7112 with doxorubicin (D) in advanced soft tissue sarcoma (ASTS).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 10514-10514	2.2	13
424	An open-label international multicentric phase II study of nilotinib in progressive pigmented villo-nodular synovitis (PVNS) not amenable to a conservative surgical treatment.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 10516-10516	2.2	6
423	Impact of mutational status and other prognostic factors on survival in patients with advanced GIST treated with standard-dose imatinib (IM): Results from the BFR14 phase III trial of the French Sarcoma Group.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 10548-10548	2.2	2
422	A large retrospective analysis of trabectedin in 885 patients with advanced soft tissue sarcoma.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 10563-10563	2.2	2
421	Gene expression patterns of hemizygous and heterozygous KIT mutations suggest distinct oncogenic pathways: a study in NIH3T3 cell lines and GIST samples. <i>PLoS ONE</i> , 2013 , 8, e61103	3.7	8
420	Les enjeux de la recherche clinique sur les tumeurs rares en Europe. <i>Bulletin De LiAcademie Nationale De Medecine</i> , 2013 , 197, 103-122	0.1	
419	Knowledge of the French population on colorectal cancer screening: Data from the EDIFICE 3 survey.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 352-352	2.2	
418	Do Our Current Clinical Trial Designs Help to Guide Clinical Practice?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013 , e381-e385	7.1	
417	Patterns of care, prognosis, and survival in patients with metastatic gastrointestinal stromal tumors (GIST) refractory to first-line imatinib and second-line sunitinib. <i>Annals of Surgical Oncology</i> , 2012 , 19, 1551-9	3.1	53

416	Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis. <i>Cancer</i> , 2012 , 118, 1649-55	6.4	171
415	Quantitative functional imaging by dynamic contrast enhanced ultrasonography (DCE-US) in GIST patients treated with masatinib. <i>Investigational New Drugs</i> , 2012 , 30, 765-71	4.3	49
414	Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2012 , 379, 1879-86	4.0	1395
413	Impaired IFN- γ production by plasmacytoid dendritic cells favors regulatory T-cell expansion that may contribute to breast cancer progression. <i>Cancer Research</i> , 2012 , 72, 5188-97	10.1	216
412	Personalised medicine in oncology: questions for the next 20 years. <i>Lancet Oncology, The</i> , 2012 , 13, 448-51	2.7	14
411	Pazopanib for metastatic soft-tissue sarcoma [Authors' reply]. <i>Lancet, The</i> , 2012 , 380, 801	4.0	
410	A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas. <i>European Journal of Cancer</i> , 2012 , 48, 3036-44	7.5	105
409	Chemotherapy in patients with desmoid tumors: a study from the French Sarcoma Group (FSG). <i>Annals of Oncology</i> , 2012 , 23, 182-186	10.3	104
408	Giant-cell tumor of bone, anti-RANKL therapy. <i>BoneKey Reports</i> , 2012 , 1, 149		23
407	First-line treatment of metastatic or locally advanced unresectable soft tissue sarcomas with conatumumab in combination with doxorubicin or doxorubicin alone: a phase I/II open-label and double-blind study. <i>European Journal of Cancer</i> , 2012 , 48, 547-63	7.5	55
406	Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas. <i>European Journal of Cancer</i> , 2012 , 48, 3027-35	7.5	94
405	Clinicians' adherence versus non adherence to practice guidelines in the management of patients with sarcoma: a cost-effectiveness assessment in two European regions. <i>BMC Health Services Research</i> , 2012 , 12, 82	2.9	40
404	Recombinant erythropoietin for the anaemia of patients with advanced Gastrointestinal Stromal Tumours (GIST) receiving imatinib: an active agent only in non progressive patients. <i>Clinical Sarcoma Research</i> , 2012 , 2, 11	2.5	2
403	Management of imatinib-associated skin rash in a patient with metastatic gastrointestinal stromal tumor: a case report. <i>Clinical Sarcoma Research</i> , 2012 , 2, 23	2.5	1
402	Analysis of genomic alterations in neuroblastoma by multiplex ligation-dependent probe amplification and array comparative genomic hybridization: a comparison of results. <i>Cancer Genetics</i> , 2012 , 205, 657-64	2.3	5
401	Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. <i>Lancet Oncology, The</i> , 2012 , 13, 1133-40	21.7	409
400	Frequencies of KIT and PDGFRA mutations in the MolecGIST prospective population-based study differ from those of advanced GISTs. <i>Medical Oncology</i> , 2012 , 29, 1765-72	3.7	72
399	Serum creatine kinase increase in patients treated with tyrosine kinase inhibitors for solid tumors. <i>Medical Oncology</i> , 2012 , 29, 3003-8	3.7	8

398	Multidisciplinarity and medical decision, impact for patients with cancer: sociological assessment of two tumour committees' organization. <i>Bulletin Du Cancer</i> , 2012 , 99, E34-42	2.4	14
397	Clinical Benefit with Regorafenib Across Subgroups and Post-Progression in Patients with Advanced Gastrointestinal Stromal Tumor (GIST) After Progression on Imatinib (IM) and Sunitinib (SU): Phase 3 Grid Trial Update. <i>Annals of Oncology</i> , 2012 , 23, ix478-ix479	10.3	2
396	Pazopanib for the treatment of soft-tissue sarcoma. <i>Clinical Pharmacology: Advances and Applications</i> , 2012 , 4, 65-70	1.5	11
395	Desmoplastic small round cell tumors with EWS-WT1 fusion transcript in children and young adults. <i>Pediatric Blood and Cancer</i> , 2012 , 58, 891-7	3	39
394	Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas. <i>Cancer</i> , 2012 , 118, 3330-6	6.4	97
393	Incidence of soft tissue sarcoma and beyond: a population-based prospective study in 3 European regions. <i>Cancer</i> , 2012 , 118, 5339-48	6.4	136
392	High-dose chemotherapy consolidation for chemosensitive advanced soft tissue sarcoma patients: an open-label, randomized controlled trial. <i>Annals of Oncology</i> , 2012 , 23, 777-784	10.3	19
391	A retrospective pooled analysis of trabectedin safety in 1,132 patients with solid tumors treated in phase II clinical trials. <i>Investigational New Drugs</i> , 2012 , 30, 1193-202	4.3	63
390	Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas. <i>Journal of Clinical Oncology</i> , 2012 , 30, 78-84	2.2	204
389	Quality of Life and Utility in Patients with Metastatic Soft Tissue and Bone Sarcoma: The Sarcoma Treatment and Burden of Illness in North America and Europe (SABINE) Study. <i>Sarcoma</i> , 2012 , 2012, 740279	3.1	47
388	Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors. <i>Annals of Oncology</i> , 2012 , 23, 1659-65	10.3	15
387	Chemotherapy treatment patterns and clinical outcomes in patients with metastatic soft tissue sarcoma. The SARcoma treatment and Burden of Illness in North America and Europe (SABINE) study. <i>Annals of Oncology</i> , 2012 , 23, 2763-2770	10.3	54
386	Desmoplastic small round cell tumor: current management and recent findings. <i>Sarcoma</i> , 2012 , 2012, 714986	3.1	74
385	Metastatic angiosarcomas: doxorubicin-based regimens, weekly paclitaxel and metastasectomy significantly improve the outcome. <i>Annals of Oncology</i> , 2012 , 23, 517-23	10.3	72
384	Sorafenib for patients with advanced angiosarcoma: a phase II Trial from the French Sarcoma Group (GSF/GETO). <i>Oncologist</i> , 2012 , 17, 260-6	5.7	153
383	Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure. <i>Clinical Cancer Research</i> , 2012 , 18, 3170-9	12.9	95
382	Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2012 , 23 Suppl 7, vii92-9	10.3	116
381	Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib. <i>Annals of Oncology</i> , 2012 , 23, 1680-7	10.3	105

380	Reply to Y. Nishida et al. <i>Journal of Clinical Oncology</i> , 2012 , 30, 1391-1391	2.2	
379	Randomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM study). <i>Oncologist</i> , 2012 , 17, 1213-20	5.7	148
378	Depression assessment by oncologists and palliative care physicians. <i>Palliative and Supportive Care</i> , 2012 , 10, 255-63	2.5	7
377	Plasmacytoid dendritic cells infiltrating ovarian cancer are associated with poor prognosis. <i>Oncolmunology</i> , 2012 , 1, 380-382	7.2	85
376	Innate immune recognition of breast tumor cells mediates CCL22 secretion favoring Treg recruitment within tumor environment. <i>Oncolmunology</i> , 2012 , 1, 759-761	7.2	19
375	Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma: an EORTC-STBSG study. <i>British Journal of Cancer</i> , 2012 , 107, 639-45	8.7	40
374	Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma. <i>Annals of Oncology</i> , 2012 , 23, 771-776	10.3	110
373	Gastrointestinal stromal tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2012 , 23 Suppl 7, vii49-55	10.3	132
372	Technology & tools development. <i>Annals of Oncology</i> , 2012 , 23, v33-v37	10.3	
371	ICOS-ligand expression on plasmacytoid dendritic cells supports breast cancer progression by promoting the accumulation of immunosuppressive CD4+ T cells. <i>Cancer Research</i> , 2012 , 72, 6130-41	10.1	134
370	Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone. <i>Clinical Cancer Research</i> , 2012 , 18, 4415-24	12.9	300
369	Advanced well-differentiated/dedifferentiated liposarcomas: role of chemotherapy and survival. <i>Annals of Oncology</i> , 2012 , 23, 1601-7	10.3	84
368	Adjuvant therapy in primary GIST: state-of-the-art. <i>Annals of Oncology</i> , 2012 , 23, 2776-2781	10.3	54
367	Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era. <i>Clinical Cancer Research</i> , 2012 , 18, 4458-64	12.9	143
366	Sarcoma: concordance between initial diagnosis and centralized expert review in a population-based study within three European regions. <i>Annals of Oncology</i> , 2012 , 23, 2442-2449	10.3	109
365	Adhesion to Clinical Practices Guidelines (CPG'S) and Role on Survival for Soft Tissue Sarcoma Patients. Analysis of a Population Based Cohort from Rhone-Alpes Region. <i>Annals of Oncology</i> , 2012 , 23, ix478	10.3	7
364	Lymphopenia combined with low TCR diversity (divpenia) predicts poor overall survival in metastatic breast cancer patients. <i>Oncolmunology</i> , 2012 , 1, 432-440	7.2	67
363	Abstract 4447: In search of the ideal cancer screening test 2012 ,		5

362	First-Line Treatment and Outcome of Elderly Patients with Primary Central Nervous System Lymphoma (PCNSL) A Systematic Review and Individual Patient Data Meta-Analysis. <i>Blood</i> , 2012 , 120, 3655-3655	2.2	1
361	A Multicentric Prospective Phase 2 Study of Intravenous Rituximab and Intrathecal Liposomal Cytarabine in Combination with CSR Protocol Followed by Brain Radiotherapy for Immunocompetent Patients with Primary CNS Lymphoma: A Lymphoma Study Association (LYSA) Trial. <i>Blood</i> , 2012 , 120, 796-796	2.2	0
360	Masitinib mesylate in imatinib-resistant advanced GIST: A randomized phase II trial.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 10007-10007	2.2	0
359	PALETTE: Final overall survival (OS) data and predictive factors for OS of EORTC 62072/GSK VEG110727, a randomized double-blind phase III trial of pazopanib versus placebo in advanced soft tissue sarcoma (STS) patients.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 10009-10009	2.2	2
358	Phase II study of sorafenib mesylate (So) in patients (pts) with evolutive and advanced epithelioid hemangioendothelioma (EHE) or hemangiopericytoma/solitary fibrous tumor (SFT).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 10020-10020	2.2	4
357	Prospective web-based collection of sarcoma cases diagnosed and treated in France: Experience of the NetSarc network of the French Sarcoma Tumor Boards.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 10056-10056 ¹	2.2	1
356	Masitinib in imatinib-naïve advanced gastrointestinal stromal tumor (GIST): Five-year follow-up of the French Sarcoma Group phase II trial.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 10089-10089	2.2	2
355	Explored prognostic factors for survival in patients with advanced GIST treated with standard dose imatinib (IM): Results from the BFR14 phase III trial of the French Sarcoma Group.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 10092-10092	2.2	3
354	A phase I study of MDM2 antagonist RG7112 in patients (pts) with relapsed/refractory solid tumors.. <i>Journal of Clinical Oncology</i> , 2012 , 30, e13600-e13600	2.2	18
353	Randomized phase III trial of regorafenib in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) progressing despite prior treatment with at least imatinib (IM) and sunitinib (SU): GRID trial.. <i>Journal of Clinical Oncology</i> , 2012 , 30, LBA10008-LBA10008	2.2	1
352	Randomized phase III trial of regorafenib in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) progressing despite prior treatment with at least imatinib (IM) and sunitinib (SU): GRID trial.. <i>Journal of Clinical Oncology</i> , 2012 , 30, LBA10008-LBA10008	2.2	9
351	Inhibition of chondrosarcoma growth by mTOR inhibitor in an in vivo syngeneic rat model. <i>PLoS ONE</i> , 2012 , 7, e32458	3.7	47
350	Le traitement médical des GIST : du palliatif au curatif. <i>Bulletin De LiAcademie Nationale De Medecine</i> , 2012 , 196, 861-884	0.1	1
349	Gastrointestinal stromal tumors (GIST): a rare entity, a tumor model for personalized therapy, and yet ten different molecular subtypes. <i>Discovery Medicine</i> , 2012 , 13, 357-67	2.5	22
348	8038 POSTER Lymphopenia is an Independent Prognostic Factor in Ovarian Cancer and Could Be Associated With Immune Activation. <i>European Journal of Cancer</i> , 2011 , 47, S538-S539	7.5	
347	Management of gastrointestinal stromal tumours of limited size: proposals from a French panel of physicians. <i>Digestive and Liver Disease</i> , 2011 , 43, 935-9	3.3	4
346	A decade of tyrosine kinase inhibitor therapy: Historical and current perspectives on targeted therapy for GIST. <i>Cancer Treatment Reviews</i> , 2011 , 37, 373-84	14.4	43
345	Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: a retrospective multicentric study. <i>European Journal of Cancer</i> , 2011 , 47, 1006-12	7.5	77

344	Soft tissue sarcomas: are all soft tissue sarcomas treated with the same drugs?. <i>European Journal of Cancer</i> , 2011 , 47 Suppl 3, S385-8	7.5	2
343	Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes. <i>Lancet Oncology</i> , 2011 , 12, 1045-52	21.7	178
342	miRNA Profiling: How to Bypass the Current Difficulties in the Diagnosis and Treatment of Sarcomas. <i>Sarcoma</i> , 2011 , 2011, 460650	3.1	14
341	Breast cancer screening in women aged 50-74 years: is there room for improvement?. <i>European Journal of Cancer Prevention</i> , 2011 , 20 Suppl 1, S8-S12	2	8
340	Use of F-18 FDG PET/CT in non-Hodgkin lymphoma with central nervous system involvement. <i>Clinical Nuclear Medicine</i> , 2011 , 36, e45-9	1.7	5
339	Uptake of breast cancer screening in women aged over 75 years: a controversy to come?. <i>European Journal of Cancer Prevention</i> , 2011 , 20 Suppl 1, S13-5	2	2
338	Screening for prostate cancer: growth without control. <i>European Journal of Cancer Prevention</i> , 2011 , 20 Suppl 1, S33-5	2	3
337	Impact of awareness of cancer among acquaintances on cancer screening attendance. <i>European Journal of Cancer Prevention</i> , 2011 , 20 Suppl 1, S36-8	2	2
336	Mammography utilization in women aged 40-49 years: the French EDIFICE survey. <i>European Journal of Cancer Prevention</i> , 2011 , 20 Suppl 1, S16-9	2	6
335	Organized colorectal cancer screening programmes: how to optimize efficiency in the general population. <i>European Journal of Cancer Prevention</i> , 2011 , 20 Suppl 1, S20-5	2	5
334	Impact of general practitioners' sex and age on systematic recommendation for cancer screening. <i>European Journal of Cancer Prevention</i> , 2011 , 20 Suppl 1, S39-41	2	13
333	CCR6/CCR10-mediated plasmacytoid dendritic cell recruitment to inflamed epithelia after instruction in lymphoid tissues. <i>Blood</i> , 2011 , 118, 5130-40	2.2	39
332	Increasing coverage rates for mammographic screening in France in older women--16 years of follow-up. <i>Breast Journal</i> , 2011 , 17, 686-8	1.2	0
331	Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. <i>Nature Medicine</i> , 2011 , 17, 700-7	50.5	244
330	Performance status is the most powerful risk factor for early death among patients with advanced soft tissue sarcoma: the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (STBSG) and French Sarcoma Group (FSG) study. <i>British Journal of Cancer</i> , 2011 , 104, 1544-50	8.7	28
329	Nilotinib: a novel, selective tyrosine kinase inhibitor. <i>Seminars in Oncology</i> , 2011 , 38 Suppl 1, S3-9	5.5	75
328	Chemotherapy for metastatic breast cancer. Comparison of clinical practice and cost of drugs in two cohorts of patients: 1994-1998 and 2003-2006. <i>Breast Cancer Research and Treatment</i> , 2011 , 128, 187-95	4.4	9
327	Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2011 , 68, 69-77	3.5	45

326	Prognostic value of the expression of C-Chemokine Receptor 6 and 7 and their ligands in non-metastatic breast cancer. <i>BMC Cancer</i> , 2011 , 11, 213	4.8	23
325	Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial. <i>BMC Cancer</i> , 2011 , 11, 72	4.8	80
324	Validation of prognostic scores for survival in cancer patients beyond first-line therapy. <i>BMC Cancer</i> , 2011 , 11, 95	4.8	27
323	Trends in survival for patients with metastatic soft-tissue sarcoma. <i>Cancer</i> , 2011 , 117, 1049-54	6.4	185
322	ERCC5/XPG, ERCC1, and BRCA1 gene status and clinical benefit of trabectedin in patients with soft tissue sarcoma. <i>Cancer</i> , 2011 , 117, 3445-56	6.4	51
321	Clinical characteristics and outcome of isolated extracerebral relapses of primary central nervous system lymphoma: a case series. <i>Hematological Oncology</i> , 2011 , 29, 10-6	1.3	21
320	Micro-RNA profiles in osteosarcoma as a predictive tool for ifosfamide response. <i>International Journal of Cancer</i> , 2011 , 129, 680-90	7.5	115
319	Quantitative and functional alterations of plasmacytoid dendritic cells contribute to immune tolerance in ovarian cancer. <i>Cancer Research</i> , 2011 , 71, 5423-34	10.1	140
318	Therapeutic pipeline for soft-tissue sarcoma. <i>Expert Opinion on Pharmacotherapy</i> , 2011 , 12, 2479-91	4	8
317	Combination therapy for gastrointestinal stromal tumors: evidence from recent clinical trials. <i>Clinical Investigation</i> , 2011 , 1, 825-836		1
316	Gastrointestinal stromal tumors of the stomach and duodenum. <i>Current Opinion in Gastroenterology</i> , 2011 , 27, 571-5	3	9
315	Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up. <i>Annals of Oncology</i> , 2011 , 22, 452-7	10.3	144
314	Tumeurs stromales gastro-intestinales 2011 , 305-325		
313	Testing new regimens in patients with advanced soft tissue sarcoma: analysis of publications from the last 10 years. <i>Annals of Oncology</i> , 2011 , 22, 1266-1272	10.3	59
312	Primary CNS lymphoma in children and adolescents: a descriptive analysis from the International Primary CNS Lymphoma Collaborative Group (IPCG). <i>Clinical Cancer Research</i> , 2011 , 17, 346-52	12.9	42
311	Updating progress in sarcoma therapy with mTOR inhibitors. <i>Annals of Oncology</i> , 2011 , 22, 280-7	10.3	38
310	Added value of molecular targeted agents in oncology. <i>Annals of Oncology</i> , 2011 , 22, 1703-16	10.3	42
309	Prognostic factors influencing progression-free survival determined from a series of sporadic desmoid tumors: a wait-and-see policy according to tumor presentation. <i>Journal of Clinical Oncology</i> , 2011 , 29, 3553-8	2.2	241

308	Early detection of tumor cells by innate immune cells leads to T(reg) recruitment through CCL22 production by tumor cells. <i>Cancer Research</i> , 2011 , 71, 6143-52	10.1	82
307	Usefulness of Positron Emission Tomography Using 18F-FDG Performed At Diagnosis and During Initial Chemotherapy for Imaging Primary Central Nervous System Lymphoma: A 24 Immunocompetent patient's Study.. <i>Blood</i> , 2011 , 118, 1597-1597	2.2	4
306	Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing. <i>PLoS ONE</i> , 2011 , 6, e20294	3.7	337
305	Evaluation in the Context of Daily Practice of Follicular Lymphoma patients' Outcome Before and After Approval of Rituximab in First Line Therapy in This Indication: Results of a Retrospective Analysis of 247 Unselected Patients with a 5-Year Median of Follow-up.. <i>Blood</i> , 2011 , 118, 3698-3698	2.2	
304	Prognostic Value of 18F-FDG Positron Emission Tomography Used for Assessment of the First Line Therapy in 410 Diffuse Large B-Cell Lymphoma Patients: A Daily Practice Evaluation Before and After the Prescription of This Metabolic Imaging Technique,. <i>Blood</i> , 2011 , 118, 3686-3686	2.2	
303	DOG1 and CD117 are the antibodies of choice in the diagnosis of gastrointestinal stromal tumours. <i>Histopathology</i> , 2010 , 57, 259-70	7.3	136
302	High frequency of beta-catenin heterozygous mutations in extra-abdominal fibromatosis: a potential molecular tool for disease management. <i>British Journal of Cancer</i> , 2010 , 102, 1032-6	8.7	105
301	A prospective epidemiological study of new incident GISTs during two consecutive years in Rhône Alpes region: incidence and molecular distribution of GIST in a European region. <i>British Journal of Cancer</i> , 2010 , 103, 165-70	8.7	82
300	Identification of biological factors predictive of response to imatinib mesylate in aggressive fibromatosis. <i>British Journal of Cancer</i> , 2010 , 103, 482-5	8.7	28
299	Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity. <i>Nature Medicine</i> , 2010 , 16, 781-7	50.5	290
298	Influenza vaccination in patients with haematologic malignancies: analysis of practices in 200 patients in a single center. <i>Bulletin Du Cancer</i> , 2010 , 97, E33-6	2.4	6
297	Tumeurs stromales gastro-intestinales (GIST) 2010 , 149-154		
296	Imatinib mesylate for the treatment of gastrointestinal stromal tumor. <i>Expert Review of Anticancer Therapy</i> , 2010 , 10, 623-34	3.5	14
295	Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2010 , 21 Suppl 5, v98-102	10.3	181
294	Pharmacological management of gastrointestinal stromal tumours: an update on the role of sunitinib. <i>Annals of Oncology</i> , 2010 , 21, 208-215	10.3	31
293	Long-term follow-up of an age-adapted C5R protocol followed by radiotherapy in 99 newly diagnosed primary CNS lymphomas: a prospective multicentric phase II study of the Groupe d'Etude des Lymphomes de l'Adulte (GELA). <i>Annals of Oncology</i> , 2010 , 21, 842-850	10.3	41
292	Effect of adjuvant chemotherapy on survival in FNCLCC grade 3 soft tissue sarcomas: a multivariate analysis of the French Sarcoma Group Database. <i>Annals of Oncology</i> , 2010 , 21, 2436-2441	10.3	81
291	A phase I-II study of everolimus (RAD001) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors. <i>Annals of Oncology</i> , 2010 , 21, 1990-1998	10.3	96

290	The estimated incidence of gastrointestinal stromal tumors in France. Results of PROGIST study conducted among pathologists. <i>Bulletin Du Cancer</i> , 2010 , 97, E16-22	2.4	37
289	Soft tissue sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2010 , 21 Suppl 5, v198-203	10.3	194
288	Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG). <i>European Journal of Cancer</i> , 2010 , 46, 72-83	7.5	189
287	Phase II study of oral masitinib mesilate in imatinib-naïve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST). <i>European Journal of Cancer</i> , 2010 , 46, 1344-51	7.5	101
286	Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI). <i>European Journal of Cancer</i> , 2010 , 46, 2206-15	7.5	78
285	Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. <i>Lancet Oncology, The</i> , 2010 , 11, 275-80	21.7	494
284	Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. <i>Lancet Oncology, The</i> , 2010 , 11, 561-70	21.7	467
283	Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial. <i>Lancet Oncology, The</i> , 2010 , 11, 942-9	21.7	217
282	Towards global consensus in the treatment of gastrointestinal stromal tumor. <i>Expert Review of Anticancer Therapy</i> , 2010 , 10, 221-32	3.5	25
281	Efficacy of trabectedin for advanced sarcomas in clinical trials versus compassionate use programs: analysis of 92 patients treated in a single institution. <i>Anti-Cancer Drugs</i> , 2010 , 21, 113-9	2.4	24
280	Serum cytokines in follicular lymphoma. Correlation of TGF- β and VEGF with survival. <i>Annals of Hematology</i> , 2010 , 89, 25-33	3	31
279	2008 French national guidelines for the treatment of venous thromboembolism in patients with cancer: report from the working group. <i>Critical Reviews in Oncology/Hematology</i> , 2010 , 73, 31-46	7	50
278	Molecular response prediction in gastrointestinal stromal tumors. <i>Targeted Oncology</i> , 2010 , 5, 29-37	5	6
277	Development and validation of a model that predicts early death among cancer patients participating in phase I clinical trials investigating cytotoxics. <i>Investigational New Drugs</i> , 2010 , 28, 76-82	4.3	23
276	Epidemiological evaluation of concordance between initial diagnosis and central pathology review in a comprehensive and prospective series of sarcoma patients in the Rhone-Alpes region. <i>BMC Cancer</i> , 2010 , 10, 150	4.8	55
275	The role of high-dose imatinib in the management of patients with gastrointestinal stromal tumor. <i>Cancer</i> , 2010 , 116, 1847-58	6.4	19
274	Perspective on updated treatment guidelines for patients with gastrointestinal stromal tumors. <i>Cancer</i> , 2010 , 116, 5126-37	6.4	55
273	Vue générale 2010 , 145-147		

272	Prognostic Impact of Elevated Serum Ferritin at Diagnosis of Diffuse Large B-Cell Lymphoma Treated In the Rituximab Era. <i>Blood</i> , 2010 , 116, 5080-5080	2.2	
271	Small cell cancer of the bladder: pathology, diagnosis, treatment and prognosis. <i>Bulletin Du Cancer</i> , 2009 , 96, E30-44	2.4	19
270	Lymphoma and myeloma cell resistance to cytotoxic agents and ionizing radiations is not affected by exposure to anti-IL-6 antibody. <i>PLoS ONE</i> , 2009 , 4, e8026	3.7	16
269	Advanced gastrointestinal stromal tumor in Europe: a review of updated treatment recommendations. <i>Expert Review of Anticancer Therapy</i> , 2009 , 9, 831-8	3.5	23
268	Trabectedin for the management of soft-tissue sarcoma. <i>Expert Review of Anticancer Therapy</i> , 2009 , 9, 727-37	3.5	5
267	Soft tissue sarcomas: ESMO clinical recommendations for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2009 , 20 Suppl 4, 132-6	10.3	47
266	Neo/adjuvant chemotherapy does not improve outcome in resected primary synovial sarcoma: a study of the French Sarcoma Group. <i>Annals of Oncology</i> , 2009 , 20, 425-30	10.3	106
265	Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). <i>Journal of Clinical Oncology</i> , 2009 , 27, 3131-38	2.2	523
264	Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial. <i>Journal of Clinical Oncology</i> , 2009 , 27, 3969-74	2.2	80
263	Gastrointestinal stromal tumours: ESMO clinical recommendations for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2009 , 20 Suppl 4, 64-7	10.3	129
262	Imatinib in gastrointestinal stromal tumor: does treatment duration matter?. <i>Oncology</i> , 2009 , 77, 157-61	3.6	2
261	Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. <i>Journal of Clinical Oncology</i> , 2009 , 27, 4188-96	2.2	408
260	A risk model for severe anemia to select cancer patients for primary prophylaxis with epoetin alpha: a prospective randomized controlled trial of the ELYPSE study group. <i>Annals of Oncology</i> , 2009 , 20, 1105-12	10.3	16
259	New paradigms in gastrointestinal stromal tumour management. <i>Annals of Oncology</i> , 2009 , 20 Suppl 1, i18-24	10.3	18
258	Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients. <i>Cancer Research</i> , 2009 , 69, 3563-9	10.1	160
257	2008 SOR guidelines for the prevention and treatment of thrombosis associated with central venous catheters in patients with cancer: report from the working group. <i>Annals of Oncology</i> , 2009 , 20, 1459-1471	10.3	92
256	Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. <i>Cancer Research</i> , 2009 , 69, 5383-91	10.1	465
255	Adjuvant chemotherapy in localized soft tissue sarcomas: still not proven. <i>Oncologist</i> , 2009 , 14, 1013-20	5.7	44

254	Cell cycle/apoptosis molecule expression correlates with imatinib response in patients with advanced gastrointestinal stromal tumors. <i>Clinical Cancer Research</i> , 2009 , 15, 4191-8	12.9	55
253	A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors. <i>Clinical Cancer Research</i> , 2009 , 15, 5910-6	12.9	94
252	Bevacizumab and paclitaxel for breast cancer patients with central nervous system metastases: a case series. <i>Clinical Breast Cancer</i> , 2009 , 9, 118-21	3	52
251	Sarcomas with spindle cell morphology. <i>Seminars in Oncology</i> , 2009 , 36, 324-37	5.5	20
250	Phase III trial of standard versus dose-intensified doxorubicin, ifosfamide and dacarbazine (MAID) in the first-line treatment of metastatic and locally advanced soft tissue sarcoma. <i>Investigational New Drugs</i> , 2009 , 27, 482-9	4.3	34
249	XXV ^e Congr ^s de la SFPO « Cancers, cultures et pratiques de soins » Paris le 28 novembre 2008 Freins et motivations au d ^e istage des cancers du sein: quels profils typologiques ? R ^s ultats issus de l'enqu ^{te} DIFICE. <i>Psycho-oncologie</i> , 2009 , 3, 60-62	0	1
248	Prognosis and predictive value of KIT exon 11 deletion in GISTs. <i>British Journal of Cancer</i> , 2009 , 101, 7-118.7		33
247	Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. <i>Cancer Research</i> , 2009 , 69, 2000-9	10.1	489
246	Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. <i>European Journal of Cancer</i> , 2009 , 45, 1959-68	7.5	284
245	Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancers. <i>European Journal of Cancer</i> , 2009 , 45, 2333-41	7.5	61
244	1LBA Impact of regional hyperthermia (RHT) on response to neo-adjuvant chemotherapy and survival of patients with high-risk soft-tissue sarcoma (HR-STs): Results of the randomized EORTC-ESHO intergroup trial (NCI-00003052). <i>European Journal of Cancer, Supplement</i> , 2009 , 7, 2	1.6	4
243	Primary retroperitoneal sarcomas: a multivariate analysis of surgical factors associated with local control. <i>Journal of Clinical Oncology</i> , 2009 , 27, 31-7	2.2	389
242	9401 Translocation-related sarcomas (TRS): a retrospective analysis of activity with trabectedin. <i>European Journal of Cancer, Supplement</i> , 2009 , 7, 590	1.6	2
241	9402 Efficacy and safety of trabectedin in soft tissue sarcoma (STS) are independent of patient age. <i>European Journal of Cancer, Supplement</i> , 2009 , 7, 590-591	1.6	2
240	9427 Efficacy of second-line trabectedin in patients with advanced liposarcomas and leiomyosarcomas progressing despite prior conventional chemotherapy. <i>European Journal of Cancer, Supplement</i> , 2009 , 7, 598	1.6	3
239	Is there a role for discontinuing imatinib in patients with advanced gastrointestinal stromal tumour?. <i>Current Opinion in Oncology</i> , 2009 , 21, 360-6	4.2	9
238	Dotlike or Golgi-like KIT and PDGFRA Staining in GISTs. <i>American Journal of Surgical Pathology</i> , 2009 , 33, 157-8; author reply 157-9	6.7	11
237	Lymphomes c ^b raux primitifs du sujet immunocomp ^t ent. <i>EMC H^umatologie</i> , 2009 , 4, 1-12		

236	Mapping the literature: role of trabectedin as a new chemotherapy option in advanced pretreated soft tissue sarcoma. <i>Drugs of Today</i> , 2009 , 45, 403-21	2.5	12
235	Accomplishments in 2008 in the management of gastrointestinal stromal tumors. <i>Gastrointestinal Cancer Research: GCR</i> , 2009 , 3, S67-72		
234	Gastrointestinal stromal tumours 2009 , 137-148		
233	Use of Chemotherapy and Immunotherapy the Last Four Weeks of life in Patients with Lymphoma in An Anticancer Center with Focus On the Impact of Time Period (1998-2002 and 2003-2008).. <i>Blood</i> , 2009 , 114, 4537-4537	2.2	
232	Treatment of Primary CNS Lymphoma in the Elderly with High-Dose Methotrexate Containing Chemotherapy Followed Radiotherapy or Chemotherapy Alone Plus Deferred Radiotherapy: Evaluation of Modification of Treatment Modalities in Leon Berard Cancer Center.. <i>Blood</i> , 2009 , 114, 2702-2702	2.2	
231	Complete Response After High-Dose Methotrexate-Based Chemotherapy as a Major Prognostic Factor for Primary CNS Lymphoma: An Exploratory Analysis of the LNHCP93 Trial of the Groupe d'Etude Des Lymphomes De l'Adulte.. <i>Blood</i> , 2009 , 114, 101-101	2.2	
230	Impact of organised programs on colorectal cancer screening. <i>BMC Cancer</i> , 2008 , 8, 104	4.8	14
229	Extra-abdominal primary fibromatosis: Aggressive management could be avoided in a subgroup of patients. <i>European Journal of Surgical Oncology</i> , 2008 , 34, 462-8	3.6	212
228	Distribution and prognostic value of histopathologic data and immunohistochemical markers in gastrointestinal stromal tumours (GISTs): An analysis of the EORTC phase III trial of treatment of metastatic GISTs with imatinib mesylate. <i>European Journal of Cancer</i> , 2008 , 44, 1855-60	7.5	30
227	Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma group. <i>European Journal of Cancer</i> , 2008 , 44, 2433-6	7.5	177
226	Gastrointestinal stromal tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2008 , 19 Suppl 2, ii35-8	10.3	98
225	Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. <i>Journal of Clinical Oncology</i> , 2008 , 26, 5269-74	2.2	469
224	KIT mutations induce intracellular retention and activation of an immature form of the KIT protein in gastrointestinal stromal tumors. <i>Clinical Cancer Research</i> , 2008 , 14, 2285-94	12.9	60
223	Soft tissue sarcomas: ESMO clinical recommendations for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2008 , 19 Suppl 2, ii89-93	10.3	88
222	Effect of cigarette smoking on imatinib in patients in the soft tissue and bone sarcoma group of the EORTC. <i>Clinical Cancer Research</i> , 2008 , 14, 8308-13	12.9	19
221	Complete response to imatinib in relapsing pigmented villonodular synovitis/tenosynovial giant cell tumor (PVNS/TGCT). <i>Annals of Oncology</i> , 2008 , 19, 821-2	10.3	116
220	A phase II study of gefitinib for patients with advanced HER-1 expressing synovial sarcoma refractory to doxorubicin-containing regimens. <i>Oncologist</i> , 2008 , 13, 467-73	5.7	47
219	Angiogenesis inhibition in non-GIST soft tissue sarcomas. <i>Oncologist</i> , 2008 , 13, 1193-200	5.7	20

218	Phase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcoma. <i>Clinical Cancer Research</i> , 2008 , 14, 6656-62	12.9	65
217	Primary CNS lymphoma with intraocular involvement: International PCNSL Collaborative Group Report. <i>Neurology</i> , 2008 , 71, 1355-60	6.5	158
216	Imatinib as a possible cause of severe rhabdomyolysis. <i>New England Journal of Medicine</i> , 2008 , 358, 2746-50	5.2	36
215	Imatinib mesilate for the treatment of gastrointestinal stromal tumour. <i>Expert Opinion on Pharmacotherapy</i> , 2008 , 9, 1211-22	4	16
214	Trabectedin and its potential in the treatment of soft tissue sarcoma. <i>Therapeutics and Clinical Risk Management</i> , 2008 , 4, 109-16	2.9	21
213	Breast cancer screening in France: results of the EDIFICE survey. <i>International Journal of Medical Sciences</i> , 2008 , 5, 106-12	3.7	8
212	Cancer screening in France: subjects' and physicians' attitudes. <i>Cancer Causes and Control</i> , 2008 , 19, 431-48	4.8	17
211	Novel approaches to gastrointestinal stromal tumors resistant to imatinib and sunitinib. <i>Current Gastroenterology Reports</i> , 2008 , 10, 555-61	5	8
210	A phase 2 trial of whole-brain radiotherapy combined with intravenous chemotherapy in patients with brain metastases from breast cancer. <i>Cancer</i> , 2008 , 113, 2532-8	6.4	15
209	Combination of rituximab with chemotherapy in diffuse large B-cell lymphoma. Evaluation in daily practice before and after approval of rituximab in this indication. <i>Hematological Oncology</i> , 2008 , 26, 139-47	1.3	6
208	Denosumab treatment of giant cell tumor of bone: Interim analysis of an open-label phase II study. <i>Journal of Clinical Oncology</i> , 2008 , 26, 10500-10500	2.2	8
207	Prognostic and predictive factors for outcome to first-line ifosfamide-containing therapy (IFM) in patients (pts) with advanced soft tissue sarcomas (STS) treated in EORTC-STBSG studies. <i>Journal of Clinical Oncology</i> , 2008 , 26, 10509-10509	2.2	2
206	A FNCLCC French Sarcoma Group GETO multicenter randomized phase II study of gemcitabine (G) versus gemcitabine and docetaxel (G+D) in patients with metastatic or relapsed leiomyosarcoma (LMS). <i>Journal of Clinical Oncology</i> , 2008 , 26, 10511-10511	2.2	8
205	Detection of β -catenin mutations in primary extra-abdominal fibromatosis (EAF): An ancillary diagnostic tool. <i>Journal of Clinical Oncology</i> , 2008 , 26, 10518-10518	2.2	4
204	A phase I-II study of everolimus (RAD001) in combination with imatinib in patients (pts) with imatinib-resistant gastrointestinal stromal tumors (GIST). <i>Journal of Clinical Oncology</i> , 2008 , 26, 10519-10519	2.2	10
203	Does interruption of imatinib (IM) in responding patients after three years of treatment influence outcome of patients with advanced GIST included in the BFR14 trial?. <i>Journal of Clinical Oncology</i> , 2008 , 26, 10522-10522	2.2	6
202	The end of adjuvant chemotherapy (adCT) era with doxorubicin-based regimen in resected high-grade soft tissue sarcoma (STS): Pooled analysis of the two STBSG-EORTC phase III clinical trials. <i>Journal of Clinical Oncology</i> , 2008 , 26, 10525-10525	2.2	28
201	A phase I study of nilotinib alone and in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors (GIST): Study update. <i>Journal of Clinical Oncology</i> , 2008 , 26, 10553-10553	2.2	15

200	Continuous daily dosing (CDD) of sunitinib (SU) in pts with advanced GIST: Updated efficacy, safety, PK and pharmacodynamic analysis. <i>Journal of Clinical Oncology</i> , 2008 , 26, 10554-10554	2.2	10
199	High response rates with isolated pelvic perfusion (IPP) with a pneumatic anti-shock garments (PASG) and low-dose TNF- α for locally advanced pelvic sarcomas and carcinomas: A phase II unicenter trial. <i>Journal of Clinical Oncology</i> , 2008 , 26, 10586-10586	2.2	2
198	Prospective Multicenter Study for Evaluating Cognitive Disorders in Hematology-Oncology: A Pilot Study of 118 Patients. <i>Blood</i> , 2008 , 112, 1309-1309	2.2	
197	Chemotherapy for osteosarcoma without high-dose methotrexate: another piece in the puzzle. <i>Oncology Research and Treatment</i> , 2007 , 30, 226-7	2.8	10
196	Reactive perivascular T-cell infiltrate predicts survival in primary central nervous system B-cell lymphomas. <i>British Journal of Haematology</i> , 2007 , 138, 316-23	4.5	53
195	Cytokines pattern after surgical radiofrequency ablation of liver colorectal metastases. <i>Gastroenterologie Clinique Et Biologique</i> , 2007 , 31, 141-5		30
194	Thérapeutiques moléculaires ciblées des sarcomes des tissus mous: actualités et perspectives. <i>Oncologie</i> , 2007 , 9, 131-136	1	
193	LESMO et la formation médicale en cancérologie. <i>Oncologie</i> , 2007 , 9, 37-40	1	
192	Standards, Options et Recommandations 2006. Prise en charge des patients adultes atteints de sarcome des tissus mous, de sarcome utérin ou de tumeur stromale gastro-intestinale. <i>Oncologie</i> , 2007 , 9, 173-177	1	6
191	Rationale and delineation of a composite index of relative antitumoural efficacy (In-RATE). <i>Critical Reviews in Oncology/Hematology</i> , 2007 , 64, 106-14	7	3
190	Emerging drugs for the treatment of soft tissue sarcomas. <i>Expert Opinion on Emerging Drugs</i> , 2007 , 12, 139-53	3.7	6
189	Primary intraocular lymphoma: an International Primary Central Nervous System Lymphoma Collaborative Group Report. <i>Annals of Oncology</i> , 2007 , 18, 1851-5	10.3	172
188	Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. <i>Journal of Clinical Oncology</i> , 2007 , 25, 3144-50	2.2	209
187	Gastrointestinal stromal tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2007 , 18 Suppl 2, ii27-9	10.3	12
186	Plasma cytokine and soluble receptor signature predicts outcome of patients with classical Hodgkin's lymphoma: a study from the Groupe d'Etude des Lymphomes de l'Adulte. <i>Journal of Clinical Oncology</i> , 2007 , 25, 1732-40	2.2	88
185	Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. <i>Journal of Clinical Oncology</i> , 2007 , 25, 1107-13	2.2	307
184	Angiosarcomas, a heterogeneous group of sarcomas with specific behavior depending on primary site: a retrospective study of 161 cases. <i>Annals of Oncology</i> , 2007 , 18, 2030-6	10.3	242
183	Brostallicin, an agent with potential activity in metastatic soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. <i>European Journal of Cancer</i> , 2007 , 43, 308-15	7.5	41

182	Exatecan in pretreated adult patients with advanced soft tissue sarcoma: results of a phase II--study of the EORTC Soft Tissue and Bone Sarcoma Group. <i>European Journal of Cancer</i> , 2007 , 43, 1017-22	7.5	25
181	Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: analysis of EORTC-ISG-AGITG study 62005. <i>European Journal of Cancer</i> , 2007 , 43, 974-8	7.5	85
180	Pressure-suit combined with pelvic stop-flow: a feasibility study in a bovine model. <i>European Journal of Surgical Oncology</i> , 2007 , 33, 114-8	3.6	4
179	Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. <i>Lancet Oncology, The</i> , 2007 , 8, 595-602	21.7	349
178	Long-Term Follow-Up of 132 Immunocompetent Primary Central Nervous System Lymphomas Treated at Leon Berard Cancer Centre: Proposition of a New Prognostic Model.. <i>Blood</i> , 2007 , 110, 521-521 ²	2.2	1
177	Weekly paclitaxel in metastatic angiosarcoma. A FNCLCC French Sarcoma Group (GSF-GETO) phase II trial. <i>Journal of Clinical Oncology</i> , 2007 , 25, 10002-10002	2.2	7
176	Continuous versus interruption of imatinib (IM) in responding patients with advanced GIST after three years of treatment: A prospective randomized phase III trial of the French Sarcoma Group. <i>Journal of Clinical Oncology</i> , 2007 , 25, 10005-10005	2.2	14
175	Continuous daily dosing (CDD) of sunitinib malate (SU) compares favorably with intermittent dosing in pts with advanced GIST. <i>Journal of Clinical Oncology</i> , 2007 , 25, 10015-10015	2.2	7
174	Paclitaxel in patients (pts) with advanced angiosarcomas. <i>Journal of Clinical Oncology</i> , 2007 , 25, 10033-10033	2.2	3
173	Survival results with AP23573, a novel mTOR inhibitor, in patients (pts) with advanced soft tissue or bone sarcomas: Update of phase II trial. <i>Journal of Clinical Oncology</i> , 2007 , 25, 10076-10076	2.2	34
172	Serum level of vascular endothelial growth factor (VEGF) as an independent prognostic factor in metastatic renal cell carcinoma (MRCC). <i>Journal of Clinical Oncology</i> , 2007 , 25, 5044-5044	2.2	15
171	NCCN Task Force Report: Management of Patients with Gastrointestinal Stromal Tumor (GIST)--Update of the NCCN Clinical Practice Guidelines. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2007 , 5, S-1-S-29	7.3	183
170	Serum Evaluation of a Panel of 10 Cytokines in Patients with Follicular Lymphoma: High Serum Level of TGF- β Correlates with Good Prognosis, Independently of the FLIPI Score.. <i>Blood</i> , 2007 , 110, 2604-2604	2.2	2
169	NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2007 , 5 Suppl 2, S1-29; quiz S30	7.3	187
168	Dendritic cells are essential for priming but inefficient for boosting antitumour immune response in an orthotopic murine glioma model. <i>Cancer Immunology, Immunotherapy</i> , 2006 , 55, 254-67	7.4	30
167	Gastrointestinal stromal tumors (GIST). <i>Gastroenterologie Clinique Et Biologique</i> , 2006 , 30, 98-101		2
166	CD40L induces multidrug resistance to apoptosis in breast carcinoma and lymphoma cells through caspase independent and dependent pathways. <i>BMC Cancer</i> , 2006 , 6, 75	4.8	24
165	Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis. <i>International Journal of Cancer</i> , 2006 , 119, 706-11	7.5	153

164	International study on low-grade primary central nervous system lymphoma. <i>Annals of Neurology</i> , 2006 , 59, 755-62	9.4	64
163	Pharmacokinetic-pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumors. <i>Clinical Cancer Research</i> , 2006 , 12, 6073-8	12.9	121
162	Management of gastrointestinal stromal tumors in the imatinib era: selected case studies. <i>Oncologist</i> , 2006 , 11, 9-20	5.7	44
161	Autoantibodies to endostatin in patients with breast cancer: correlation to endostatin levels and clinical outcome. <i>British Journal of Cancer</i> , 2006 , 94, 1066-70	8.7	31
160	KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. <i>European Journal of Cancer</i> , 2006 , 42, 1093-103	7.5	701
159	Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: a study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC-ISG-AGITG). <i>European</i>	7.5	82
158	Phase 1 European Organisation for Research and Treatment of Cancer study determining safety of pegylated liposomal doxorubicin (Caelyx) in combination with ifosfamide in previously untreated adult patients with advanced or metastatic soft tissue sarcomas. <i>European Journal of Cancer</i> , 2006 , 42, 2303-9	7.5	7
157	Sarcomas and malignant phyllodes tumours of the breast--a retrospective study. <i>European Journal of Cancer</i> , 2006 , 42, 2715-21	7.5	77
156	Gastrointestinal stromal tumours: consensus statement on diagnosis and treatment. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2006 , 20, 157-63		98
155	ET-743: a novel agent with activity in soft-tissue sarcomas. <i>Current Opinion in Oncology</i> , 2006 , 18, 347-53	4.2	47
154	Incidence and prognostic value of tumour cells detected by RT-PCR in peripheral blood stem cell collections from patients with Ewing tumour. <i>British Journal of Cancer</i> , 2006 , 95, 1326-33	8.7	22
153	Anticorps anti-VEGF: un emploi universel?. <i>Oncologie</i> , 2006 , 8, 808-814	1	
152	Toxicité cutanée des anti-EGF-R. <i>Oncologie</i> , 2006 , 8, 889-894	1	1
151	Nouvelles approches dans les thérapies ciblées: les récepteurs des facteurs de croissance de type insuline et les cyclines. <i>Oncologie</i> , 2006 , 8, 835-841	1	
150	Updated results of a phase II trial of AP23573, a novel mTOR inhibitor, in patients (pts) with advanced soft tissue or bone sarcomas. <i>Journal of Clinical Oncology</i> , 2006 , 24, 9505-9505	2.2	39
149	Is a stable disease according to RECIST criteria a real stable disease in GIST patients treated with imatinib mesylate (IM) included in the intergroup EORTC/ISG/AGITG trial?. <i>Journal of Clinical Oncology</i> , 2006 , 24, 9510-9510	2.2	6
148	Patterns of tumor response to trabectedin (ET743) in myxoid liposarcomas. <i>Journal of Clinical Oncology</i> , 2006 , 24, 9511-9511	2.2	12
147	DNA repair functionality modulates the clinical outcome of patients with advanced sarcoma treated with trabectedin (ET-743). <i>Journal of Clinical Oncology</i> , 2006 , 24, 9522-9522	2.2	15

146	Les thérapies ciblées ou le traitement des mécanismes moléculaires de la progression tumorale 2006 , 515-527		
145	Lymphopenia Prior High-Dose Chemotherapy Is a Major Prognostic Factor for Severe Infectious Complication after Autologous Blood Stem Cell Transplantation for Lymphoma Patients.. <i>Blood</i> , 2006 , 108, 2984-2984	2.2	
144	CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. <i>Journal of Experimental Medicine</i> , 2005 , 202, 1075-85	16.6	687
143	Lymphopenia: a new independent prognostic factor for survival in patients treated with whole brain radiotherapy for brain metastases from breast carcinoma. <i>Radiotherapy and Oncology</i> , 2005 , 76, 334-9	5.3	43
142	Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. <i>Annals of Oncology</i> , 2005 , 16, 566-78	10.3	518
141	Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. <i>Journal of Clinical Oncology</i> , 2005 , 23, 576-84	2.2	350
140	Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. <i>European Journal of Cancer</i> , 2005 , 41, 1751-7	7.5	298
139	Randomized trial of cytoreduction followed by intraperitoneal chemotherapy versus cytoreduction alone in patients with peritoneal sarcomatosis. <i>European Journal of Surgical Oncology</i> , 2005 , 31, 917-23	3.6	58
138	Genetic predictors for drug resistance in soft tissue sarcoma: a review of publications in 2004. <i>Current Opinion in Oncology</i> , 2005 , 17, 370-5	4.2	7
137	Decision making process in oncology practice: is the information available and what should it consist of?. <i>Critical Reviews in Oncology/Hematology</i> , 2005 , 54, 165-70	7	6
136	Tumeurs rares malignes de l'ovaire. <i>Oncologie</i> , 2005 , 7, 556-563	1	1
135	Corrections to Consensus meeting for the management of gastrointestinal stromal tumors Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. <i>Annals of Oncology</i> , 2005 , 16, 993	10.3	4
134	Primary CNS lymphoma of T-cell origin: a descriptive analysis from the international primary CNS lymphoma collaborative group. <i>Journal of Clinical Oncology</i> , 2005 , 23, 2233-9	2.2	167
133	ET-743: a novel agent with activity in soft tissue sarcomas. <i>Oncologist</i> , 2005 , 10, 827-32	5.7	38
132	Early variations of circulating interleukin-6 and interleukin-10 levels during thoracic radiotherapy are predictive for radiation pneumonitis. <i>Journal of Clinical Oncology</i> , 2005 , 23, 8748-56	2.2	113
131	Limb salvage with isolated perfusion for soft tissue sarcoma: could less TNF-alpha be better?. <i>Annals of Oncology</i> , 2005 , 16, 1061-8	10.3	97
130	A phase I/II trial of the oral mTOR-inhibitor everolimus (E) and imatinib mesylate (IM) in patients (pts) with gastrointestinal stromal tumor (GIST) refractory to IM: Study update. <i>Journal of Clinical Oncology</i> , 2005 , 23, 9033-9033	2.2	23
129	Comparison of Outcome of Unselected Patients with Diffuse Large B-Cell Lymphoma Diagnosed before and after Approval of Rituximab in France in This Indication.. <i>Blood</i> , 2005 , 106, 4766-4766	2.2	

128	International Primary Central Nervous System Lymphoma Collaborative Group (IPCG) Study on Low-Grade Primary Central Nervous System Lymphoma in Immunocompetent Patients.. <i>Blood</i> , 2005 , 106, 3343-3343	2.2	1
127	A spliced isoform of interleukin 6 mRNA produced by renal cell carcinoma encodes for an interleukin 6 inhibitor. <i>Cancer Research</i> , 2005 , 65, 2-5	10.1	17
126	Targeted cancer therapies. <i>Bulletin Du Cancer</i> , 2005 , 92, E13-8	2.4	15
125	Coexpression of CD40 and CD40L on B lymphoma and carcinoma cells: an autocrine anti-apoptotic role. <i>Leukemia and Lymphoma</i> , 2004 , 45, 1239-45	1.9	20
124	Targeting other abnormal signaling pathways in sarcoma: EGFR in synovial sarcomas, PPAR-gamma in liposarcomas. <i>Cancer Treatment and Research</i> , 2004 , 120, 151-67	3.5	12
123	Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. <i>Journal of Clinical Oncology</i> , 2004 , 22, 890-9	2.2	260
122	The immunosuppressive effect of vincristine on allostimulatory potential of human dendritic cells interferes with their function and survival. <i>International Journal of Oncology</i> , 2004 , 25, 407-12	1	3
121	Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6--from the Groupe Francais d'Immunotherapie. <i>Journal of Clinical Oncology</i> , 2004 , 22, 2371-8	2.2	142
120	Second autologous transplantation after failure of a first autologous transplant in 18 patients with non-Hodgkin's lymphoma. <i>The Hematology Journal</i> , 2004 , 5, 403-9		11
119	CD4 lymphopenia as a risk factor for febrile neutropenia and early death after cytotoxic chemotherapy in adult patients with cancer. <i>Cancer</i> , 2004 , 101, 2675-80	6.4	72
118	Breast carcinoma cells promote the differentiation of CD34+ progenitors towards 2 different subpopulations of dendritic cells with CD1a(high)CD86(-)Langerin- and CD1a(+)CD86(+)Langerin+ phenotypes. <i>International Journal of Cancer</i> , 2004 , 110, 710-20	7.5	44
117	IL-6 as an intracrine growth factor for renal carcinoma cell lines. <i>International Journal of Cancer</i> , 2004 , 111, 653-61	7.5	61
116	Combination treatment of rituximab and imatinib mesylate for simultaneous relapse of MALT lymphoma and a gastrointestinal stromal tumor. <i>Leukemia and Lymphoma</i> , 2004 , 45, 2353-4	1.9	3
115	Conformity to clinical practice guidelines, multidisciplinary management and outcome of treatment for soft tissue sarcomas. <i>Annals of Oncology</i> , 2004 , 15, 307-15	10.3	132
114	Les cellules dendritiques dans le microenvironnement tumoral. <i>Annales De Pathologie</i> , 2004 , 24, 36-37	0.3	
113	Dendritic cell infiltration and prognosis of early stage breast cancer. <i>Clinical Cancer Research</i> , 2004 , 10, 7466-74	12.9	339
112	A phase II study of ET-743/trabectedin ('Yondelis') for patients with advanced gastrointestinal stromal tumours. <i>European Journal of Cancer</i> , 2004 , 40, 1327-31	7.5	47
111	Imatinib in patients with metastatic gastrointestinal stromal tumours relapsing after hepatic transplantation. <i>European Journal of Cancer</i> , 2004 , 40, 1456-7	7.5	4

110	Results of a randomised phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancer. <i>European Journal of Cancer</i> , 2004 , 40, 2071-6	7.5	94
109	Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. <i>Lancet, The</i> , 2004 , 364, 1127-34	4.0	1354
108	Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. <i>Journal of Clinical Investigation</i> , 2004 , 114, 379-88	15.9	218
107	Outcome of patients with advanced gastro-intestinal stromal tumors (GIST) crossing over to a daily imatinib dose of 800mg (HD) after progression on 400mg (LD) - an international, intergroup study of the EORTC, ISG and AGITG. <i>Journal of Clinical Oncology</i> , 2004 , 22, 9004-9004	2.2	7
106	Continuous vs intermittent imatinib treatment in advanced GIST after one year: A prospective randomized phase III trial of the French Sarcoma Group. <i>Journal of Clinical Oncology</i> , 2004 , 22, 9006-9006 ^{2.2}	2.2	13
105	First interim report on the randomized EORTC 62961/ESHO-RHT 95 Intergroup Study (phase III) combined with regional hyperthermia (RHT) versus chemotherapy alone in the treatment of high-risk soft tissue sarcomas (HR-STS) in adults. <i>Journal of Clinical Oncology</i> , 2004 , 22, 9015-9015	2.2	2
104	Outcome of patients with advanced gastro-intestinal stromal tumors (GIST) crossing over to a daily imatinib dose of 800mg (HD) after progression on 400mg (LD) - an international, intergroup study of the EORTC, ISG and AGITG. <i>Journal of Clinical Oncology</i> , 2004 , 22, 9004-9004	2.2	5
103	Continuous vs intermittent imatinib treatment in advanced GIST after one year: A prospective randomized phase III trial of the French Sarcoma Group. <i>Journal of Clinical Oncology</i> , 2004 , 22, 9006-9006 ^{2.2}	2.2	11
102	First interim report on the randomized EORTC 62961/ESHO-RHT 95 Intergroup Study (phase III) combined with regional hyperthermia (RHT) versus chemotherapy alone in the treatment of high-risk soft tissue sarcomas (HR-STS) in adults. <i>Journal of Clinical Oncology</i> , 2004 , 22, 9015-9015	2.2	
101	Primary Central Nervous System Lymphoma of T Cell Origin: A Descriptive Analysis of 45 Cases from the International PCNSL Collaborative Group.. <i>Blood</i> , 2004 , 104, 1372-1372	2.2	
100	Baseline and early lymphopenia predict for the risk of febrile neutropenia after chemotherapy. <i>British Journal of Cancer</i> , 2003 , 88, 181-6	8.7	88
99	Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients. <i>British Journal of Cancer</i> , 2003 , 88, 1721-6	8.7	241
98	Gastrointestinal stromal tumors: biology and treatment. <i>Oncology</i> , 2003 , 65, 187-97	3.6	96
97	Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy. <i>European Journal of Cancer</i> , 2003 , 39, 64-9	7.5	149
96	Imatinib mesylate (STI-571 Glivec [®] , Gleevec [®]) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. <i>European Journal of Cancer</i> , 2003 , 39, 2006-2011	7.5	339
95	Evaluation of core needle biopsy as a substitute to open biopsy in the diagnosis of soft-tissue masses. <i>European Journal of Cancer</i> , 2003 , 39, 2021-5	7.5	74
94	Metastatic Soft Tissue Sarcoma in Adults. <i>American Journal of Cancer</i> , 2003 , 2, 211-221		19
93	Risk model predictive of severe anemia requiring RBC transfusion after chemotherapy in pediatric solid tumor patients. <i>Journal of Clinical Oncology</i> , 2003 , 21, 4235-8	2.2	13

92	Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. <i>Journal of Clinical Oncology</i> , 2003 , 21, 266-72	2.2	539
91	Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. <i>European Journal of Cancer</i> , 2003 , 39, 2001-14	7.5	96
90	Randomized, controlled, dose-range study of Ro 25-8315 given before and after a high-dose combination chemotherapy regimen in patients with metastatic or recurrent breast cancer patients. <i>Journal of Clinical Oncology</i> , 2002 , 20, 24-36	2.2	15
89	Randomized, Controlled, Dose-Range Study of Ro 25-8315 Given Before and After a High-Dose Combination Chemotherapy Regimen in Patients With Metastatic or Recurrent Breast Cancer Patients. <i>Journal of Clinical Oncology</i> , 2002 , 20, 24-36	2.2	8
88	A phase I/II study of 4 monthly courses of high-dose cyclophosphamide and thiotepa for metastatic breast cancer patients. <i>British Journal of Cancer</i> , 2002 , 87, 1079-85	8.7	3
87	A multicenter study of treatment of primary CNS lymphoma. <i>Neurology</i> , 2002 , 58, 1513-20	6.5	278
86	Relevance of intraocular involvement in the management of primary central nervous system lymphomas. <i>Annals of Oncology</i> , 2002 , 13, 531-8	10.3	105
85	Gemcitabine in advanced adult soft-tissue sarcomas. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. <i>European Journal of Cancer</i> , 2002 , 38, 556-9	7.5	99
84	Clinical relevance of consolidation radiotherapy and other main therapeutic issues in primary central nervous system lymphomas treated with upfront high-dose methotrexate. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001 , 51, 419-25	4	76
83	Identification of patients at risk for early death after conventional chemotherapy in solid tumours and lymphomas. <i>British Journal of Cancer</i> , 2001 , 85, 816-22	8.7	59
82	Commentary on Advances in the Therapy of Primary Central Nervous System Lymphoma <i>Clinical Lymphoma and Myeloma</i> , 2001 , 1, 276		1
81	Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. <i>European Journal of Cancer</i> , 2001 , 37, 870-7	7.5	293
80	Consistent evidence of activity of ecteinascidin (ET-743) in pretreated, advanced soft tissue sarcoma (ASTS): results from a pooled analysis of three pivotal phase II clinical trials (p2ct) and safety profile of a 24 h infusion schedule. <i>European Journal of Cancer</i> , 2001 , 37, S34	7.5	9
79	Complete response of an HIV negative gastric Kaposi's sarcoma (KS) patient with peritoneal carcinomatosis by liposomal daunorubicin treatment. <i>Annals of Oncology</i> , 2001 , 12, 275-6	10.3	
78	Osteosarcoma. <i>British Journal of Cancer</i> , 2001 , 84 Suppl 2, 78-80	8.7	8
77	IL-4 prevents the blockade of dendritic cell differentiation induced by tumor cells. <i>Cancer Research</i> , 2001 , 61, 3096-104	10.1	55
76	Research controversies in management of oral mucositis. <i>Supportive Care in Cancer</i> , 2000 , 8, 68-71	3.9	35
75	Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group. <i>Journal of Clinical Oncology</i> , 2000 , 18, 2676-84	2.2	231

74	High-dose chemotherapy with autologous hematopoietic stem-cell transplantation for advanced soft tissue sarcoma in adults. <i>Journal of Clinical Oncology</i> , 2000 , 18, 3643-50	2.2	60
73	A prospective study of the LMB regimen for diffuse large cell non Hodgkin's lymphoma in adults. <i>Leukemia and Lymphoma</i> , 2000 , 36, 525-32	1.9	2
72	Primary cerebral lymphomas: Unsolved issues regarding first-line treatment, follow-up, late neurological toxicity and treatment of relapses. <i>Annals of Oncology</i> , 2000 , 11, S39-S44	10.3	11
71	Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. <i>European Journal of Cancer</i> , 2000 , 36, 61-7	7.5	108
70	. <i>Annals of Oncology</i> , 2000 , 11, 39-44	10.3	11
69	Phase II study of 3-hour infusion of high dose paclitaxel in refractory and relapsed aggressive non-Hodgkin's lymphomas. Groupe d'Etude des Lymphomes de l'Adulte. <i>Haematologica</i> , 2000 , 85, 502-7	6.6	11
68	Risk model for severe anemia requiring red blood cell transfusion after cytotoxic conventional chemotherapy regimens. The Elypse 1 Study Group. <i>Journal of Clinical Oncology</i> , 1999 , 17, 2840-6	2.2	67
67	High-dose methotrexate and HELP [Holoxan (ifosfamide), eldesine (vindesine), platinum]--doxorubicin in non-metastatic osteosarcoma of the extremity: a French multicentre pilot study. Fédération Nationale des Centres de Lutte contre le Cancer and Société Française d'Oncologie Pédiatrique. <i>Annals of Oncology</i> , 1999 , 10, 1665-71	10.3	28
66	Renal cell carcinoma induces interleukin 10 and prostaglandin E2 production by monocytes. <i>British Journal of Cancer</i> , 1999 , 79, 119-30	8.7	48
65	Assessment of osteosarcoma response to neoadjuvant chemotherapy: comparative usefulness of dynamic gadolinium-enhanced spin-echo magnetic resonance imaging and technetium-99m skeletal angioscintigraphy. <i>European Radiology</i> , 1999 , 9, 907-14	8	29
64	Chemotherapy for patients with locally advanced or metastatic Merkel cell carcinoma. <i>Cancer</i> , 1999 , 85, 2589-95	6.4	208
63	Phase II study of raltitrexed ('Tomudex') for patients with advanced soft tissue sarcomas refractory to doxorubicin-containing regimens. <i>Anti-Cancer Drugs</i> , 1999 , 10, 873-7	2.4	14
62	Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline- and/or paclitaxel-containing regimens. <i>Cancer</i> , 1998 , 82, 134-140	6.4	36
61	Les cytokines: outils et cibles privilégiés dans l'immuno-surveillance du cancer. <i>Annales De L'institut Pasteur / Actualités</i> , 1998 , 9, 121-130		
60	High-dose chemotherapy with hematopoietic stem cell transplantation in patients with mantle cell or diffuse centrocytic non-Hodgkin's lymphomas: a single center experience on 18 patients. <i>Bone Marrow Transplantation</i> , 1998 , 21, 51-4	4.4	33
59	High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series. <i>Journal of Clinical Oncology</i> , 1998 , 16, 864-71	2.2	265
58	Ewing's family of tumors in adults: multivariate analysis of survival and long-term results of multimodality therapy in 182 patients. <i>Journal of Clinical Oncology</i> , 1998 , 16, 3736-43	2.2	100
57	Inhibition of the Differentiation of Dendritic Cells From CD34+ Progenitors by Tumor Cells: Role of Interleukin-6 and Macrophage Colony-Stimulating Factor. <i>Blood</i> , 1998 , 92, 4778-4791	2.2	468

56	A Risk Model for Thrombocytopenia Requiring Platelet Transfusion After Cytotoxic Chemotherapy. <i>Blood</i> , 1998 , 92, 405-410	2.2	95
55	Resistance to Cytotoxic Chemotherapy Induced by CD40 Ligand in Lymphoma Cells. <i>Blood</i> , 1998 , 92, 3381-3387	2.2	45
54	Inhibition of the Differentiation of Dendritic Cells From CD34+ Progenitors by Tumor Cells: Role of Interleukin-6 and Macrophage Colony-Stimulating Factor. <i>Blood</i> , 1998 , 92, 4778-4791	2.2	83
53	A Risk Model for Thrombocytopenia Requiring Platelet Transfusion After Cytotoxic Chemotherapy. <i>Blood</i> , 1998 , 92, 405-410	2.2	
52	A risk model for thrombocytopenia requiring platelet transfusion after cytotoxic chemotherapy. <i>Blood</i> , 1998 , 92, 405-10	2.2	12
51	Resistance to cytotoxic chemotherapy induced by CD40 ligand in lymphoma cells. <i>Blood</i> , 1998 , 92, 3381-3387	2.2	11
50	Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor. <i>Blood</i> , 1998 , 92, 4778-91	2.2	170
49	Phase I study of interleukin-6 in children with solid tumours in relapse. <i>European Journal of Cancer</i> , 1997 , 33, 1620-6	7.5	10
48	Elderly patients with aggressive non-Hodgkin's lymphoma: disease presentation, response to treatment, and survival--a Groupe d'Etude des Lymphomes de l'Adulte study on 453 patients older than 69 years. <i>Journal of Clinical Oncology</i> , 1997 , 15, 2945-53	2.2	181
47	Correlation between clinical response to interleukin 2 and HLA phenotypes in patients with metastatic renal cell carcinoma. <i>British Journal of Cancer</i> , 1997 , 75, 283-6	8.7	16
46	The host-tumor immune conflict: from immunosuppression to resistance and destruction. <i>Trends in Immunology</i> , 1997 , 18, 493-7		298
45	Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma. <i>International Journal of Cancer</i> , 1997 , 72, 424-30	7.5	176
44	Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma 1997 , 72, 424		5
43	Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia. <i>Journal of Clinical Oncology</i> , 1996 , 14, 636-43	2.2	124
42	Predictors of clinical response to interleukin-2--based immunotherapy in melanoma patients: a French multiinstitutional study. <i>Journal of Clinical Oncology</i> , 1996 , 14, 1697-703	2.2	85
41	Tolerance evaluation of L-asparaginase loaded in red blood cells. <i>European Journal of Clinical Pharmacology</i> , 1996 , 51, 221-5	2.8	47
40	Serum interleukin-12 levels in patients undergoing allogeneic or autologous bone marrow transplantation. <i>European Cytokine Network</i> , 1996 , 7, 389-94	3.3	8
39	Interleukin (IL)-10 and IL-6 are produced in vivo by non-Hodgkin's lymphoma cells and act as cooperative growth factors. <i>Cancer Research</i> , 1996 , 56, 5499-505	10.1	138

38	Presence of Epstein-Barr virus viral interleukin-10 in the serum of patients with non-human-immunodeficiency-virus-related diffuse large- cell non-Hodgkin's lymphomas [letter; comment]. <i>Blood</i> , 1995 , 86, 4702-4704	2.2	16
37	The C5R protocol: a regimen of high-dose chemotherapy and radiotherapy in primary cerebral non-Hodgkin's lymphoma of patients with no known cause of immunosuppression [see comments]. <i>Blood</i> , 1995 , 86, 2922-2929	2.2	102
36	Hepatic angiosarcoma in a patient with essential thrombocythaemia and Budd-Chiari syndrome. <i>European Journal of Cancer</i> , 1995 , 31A, 423	7.5	3
35	Prognostic factors in chordoma: role of postoperative radiotherapy. <i>European Journal of Cancer</i> , 1995 , 31A, 2255-9	7.5	54
34	Adoptive Immunotherapy with Interleukin-2 and LAK Cells or Gene Modified TIL in Patients with Renal Cell Carcinoma: Clinical and Laboratory Data 1995 , 249-253		
33	Administration of an anti-interleukin-6 monoclonal antibody to patients with acquired immunodeficiency syndrome and lymphoma: effect on lymphoma growth and on B clinical symptoms. <i>Blood</i> , 1994 , 84, 2472-2479	2.2	107
32	Local production of interleukin 6 by renal adenocarcinoma in vivo. <i>Journal of the National Cancer Institute</i> , 1994 , 86, 238	9.7	19
31	The role of fast neutron therapy in unresectable pelvic osteosarcoma: preliminary report. <i>Medical and Pediatric Oncology</i> , 1994 , 22, 355-7		12
30	Subcutaneous low-dose recombinant interleukin 2 and alpha-interferon in patients with metastatic renal cell carcinoma. <i>British Journal of Cancer</i> , 1994 , 69, 1111-4	8.7	38
29	Pretreatment serum CRP and response to interleukin 2. <i>British Journal of Cancer</i> , 1994 , 69, 200-1	8.7	11
28	Serum concentrations of cytokines in patients with Hodgkin's disease. <i>European Journal of Cancer</i> , 1994 , 30A, 321-4	7.5	20
27	Failure of high-dose alkylating agents in osteosarcoma. Solid Tumors Working Party. <i>Bone Marrow Transplantation</i> , 1994 , 14, 665-6	4.4	11
26	Interleukin-2 Therapy: Report on 129 Patients and Three Different Schedules 1994 , 56-62		1
25	Medulloblastoma in adults: survival and prognostic factors. <i>Radiotherapy and Oncology</i> , 1993 , 29, 301-7	5.3	31
24	Patients with metastatic renal carcinoma candidate for immunotherapy with cytokines. Analysis of a single institution study on 181 patients. <i>British Journal of Cancer</i> , 1993 , 68, 1036-42	8.7	15
23	Serum interleukin-10 in non-Hodgkin's lymphoma: a prognostic factor. <i>Blood</i> , 1993 , 82, 2169-2174	2.2	220
22	Role of interleukin-6 in paraneoplastic thrombocytosis [letter]. <i>Blood</i> , 1993 , 82, 2261-2262	2.2	57
21	Multivariate analysis of prognostic factors in patients with non HIV-related primary cerebral lymphoma. A proposal for a prognostic scoring. <i>British Journal of Cancer</i> , 1993 , 67, 1136-41	8.7	29

20	Serum interleukin-10 in non-Hodgkin's lymphoma: a prognostic factor. <i>Blood</i> , 1993 , 82, 2169-74	2.2	57
19	Intravenous interleukin-2 in patients over 65 with metastatic renal carcinoma. <i>British Journal of Cancer</i> , 1992 , 65, 723-6	8.7	18
18	Tumor necrosis factor as an autocrine growth factor for neuroblastoma. <i>Cancer Research</i> , 1992 , 52, 3194-200	4.0	40
17	High dose chemotherapy with ABMT in soft tissue sarcomas: a report of 22 cases. <i>Bone Marrow Transplantation</i> , 1992 , 10, 405-8	4.4	28
16	Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. <i>Cancer Research</i> , 1992 , 52, 3317-22	10.1	288
15	Management of pediatric non-Hodgkin's lymphoma. <i>Blood Reviews</i> , 1991 , 5, 90-7	11.1	14
14	Functional interactions between interleukin-4, interleukin-2, and tumor necrosis factor-alpha for lymphokine-activated killer cell generation. <i>Journal of Clinical Laboratory Analysis</i> , 1990 , 4, 54-8	3	1
13	TNF alpha enhancement of NK and LAK cell functions induced by high-dose IL-2 in human peripheral blood mononuclear cells from patients pretreated with alpha IFN + IL-2. <i>European Cytokine Network</i> , 1990 , 1, 221-7	3.3	3
12	Functional and phenotypic modifications induced by IL-4, as single agent or in combination with IL-2, on PBMC preactivated in vivo by alpha-interferon + interleukin-2 therapy. <i>European Cytokine Network</i> , 1990 , 1, 141-7	3.3	1
11	Evidence for tumor necrosis factor-alpha involvement in the optimal induction of class I allospecific cytotoxic T cells. <i>Journal of Immunology</i> , 1990 , 144, 4555-61	5.3	37
10	Correlation between clinical response to interleukin 2 therapy and sustained production of tumor necrosis factor. <i>Cancer Research</i> , 1990 , 50, 2371-4	10.1	73
9	Hormonal and metabolic effects of chronic interleukin-2 infusion in cancer patients. <i>Journal of Biological Response Modifiers</i> , 1990 , 9, 251-5		4
8	Involvement of cyclic adenosine monophosphate in the interleukin 4 inhibitory effect on interleukin 2-induced lymphokine-activated killer generation. <i>Journal of Clinical Investigation</i> , 1990 , 85, 1909-13	15.9	15
7	Functional interactions of IL2 and TNF in the differentiation of LGL into LAK effectors. <i>International Journal of Cancer</i> , 1989 , 44, 598-604	7.5	26
6	Generation of lymphokine-activated killer cells: synergy between tumor necrosis factor and interleukin 2. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1988 , 85, 6875-9	11.5	63
5			1
4	ATRX alteration contributes to tumor growth and immune escape in pleomorphic sarcomas		1
3	Prognosis and predictive value of KIT exon 11 deletion in GISTs		1

2 SRF-MYOCD axis is the targetable driver of a well differentiated aggressive subtype of leiomyosarcomas 2

1	Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort. <i>Nature Medicine</i> ,	50.5	5
---	--	------	---